Asian pacific association for the study of the liver consensus recommendations on hepatocellular carcinoma

Hepatology International

Volumn 4, Issue 2, 2010, Pages 439-474

  Omata, Masao ^a   Lesmana, Laurentius A ^b   Tateishi, Ryosuke ^a   Chen, Pei Jer ^c   Lin, Shi Ming ^d   Yoshida, Haruhiko ^a   Kudo, Masatoshi ^e   Lee, Jeong Min ^f   Choi, Byung Ihn ^f   Poon, Ronnie T P ^g   Shiina, Shuichiro ^a   Cheng, Ann Lii ^c   Jia, Ji Dong ^h   Obi, Shuntaro ⁱ   Han, Kwang Hyub ^j   Jafri, Wasim ^k   Chow, Pierce ^l   Lim, Seng Gee ^m   Chawla, Yogesh K ⁿ   Budihusodo, Unggul ^b   Gani, Rino A ^o   Lesmana, C Rinaldi ^b   Putranto, Terawan Agus ^p   Liaw, Yun Fan ^d   Sarin, Shiv Kumar ^q   more..

^a UNIVERSITY OF TOKYO   (Japan)

^b UNIVERSITY OF INDONESIA   (Indonesia)

^c NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^d CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^e KINKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^f Seoul National University Hospital   (South Korea)

^g UNIVERSITY OF HONG KONG   (Hong Kong)

^h CAPITAL MEDICAL UNIVERSITY   (China)

ⁱ Kyoundo Hospital   (Japan)

^j Yonsei University College of Medicine   (South Korea)

^k AGA KHAN UNIVERSITY HOSPITAL   (Pakistan)

^l SINGAPORE GENERAL HOSPITAL   (Singapore)

^m NATIONAL UNIVERSITY HOSPITAL   (Singapore)

ⁿ POSTGRADUATE INSTITUTE OF MEDICAL EDUCATION AND RESEARCH   (India)

^o CIPTO MANGUNKUSUMO HOSPITAL   (Indonesia)

^p Department of Radiology   (Indonesia)

^q UNIVERSITY OF DELHI   (India)

more..

Author keywords

Consensus statements; Diagnosis; Epidemiology; Hepatocellular carcinoma; Recommendations; Treatment algorithm

Indexed keywords

AFLATOXIN; ALPHA FETOPROTEIN; BEVACIZUMAB; CAPECITABINE; CETUXIMAB; CISPLATIN; DECARBOXYPROTHROMBIN; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; EPIRUBICIN; ERLOTINIB; FARNOQUINONE; FLUOROURACIL; GEFITINIB; GEMCITABINE; GLITAZONE DERIVATIVE; GLYPICAN 3; HEPATITIS B VACCINE; INTERFERON; LAMIVUDINE; METFORMIN; MITOMYCIN C; MITOXANTRONE; OXALIPLATIN; PLACEBO; SORAFENIB; SUNITINIB; THALIDOMIDE; TUMOR MARKER; UNINDEXED DRUG;

ADVANCED CANCER; ALCOHOL CONSUMPTION; ANTINEOPLASTIC ACTIVITY; ASCITES; BLEEDING; BONE MARROW SUPPRESSION; CANCER SCREENING; CARDIOTOXICITY; CHEMOEMBOLIZATION; CLINICAL TRIAL; COFFEE; COMPUTER ASSISTED TOMOGRAPHY; CONSTIPATION; DESQUAMATION; DIAGNOSTIC TEST; DIARRHEA; DIZZINESS; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; DRUG TOLERABILITY; ECHOGRAPHY; EDEMA; EVIDENCE BASED MEDICINE; FAMILY HISTORY; FATIGUE; GEOGRAPHIC DISTRIBUTION; HAND FOOT SYNDROME; HEMOCHROMATOSIS; HEPATIC ENCEPHALOPATHY; HEPATITIS B; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERTENSION; INFECTION; INSULIN RESISTANCE; LIVER CARCINOMA; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER RESECTION; LIVER TRANSPLANTATION; LOADING DRUG DOSE; LYMPHOCYTOPENIA; MEDICAL SPECIALIST; MIXED INFECTION; NEUTROPENIA; NONALCOHOLIC FATTY LIVER; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PRIMARY PREVENTION; PRIORITY JOURNAL; RADIOFREQUENCY ABLATION; REVIEW; SECONDARY PREVENTION; SENSITIVITY AND SPECIFICITY; SEX DIFFERENCE; SIDE EFFECT; SMOKING; SOMNOLENCE; THROMBOCYTOPENIA; THROMBOSIS; VACCINATION; VIRUS TRANSMISSION;

EID: 84984586846     PISSN: 19360533     EISSN: 19360541     Source Type: Journal    
DOI: 10.1007/s12072-010-9165-7     Document Type: Review

References (413)

1. Centre for Evidence-Based Medicine. Levels of evidence 2001 [cited 1 Dec 2008]. http://www.cebm.net/index.aspx?o=1025
2. Parkin DM, Whelan SL, Ferlay J, Teppo L, Thomas DB. Cancer Incidence in Five Continents, vol. VIII. Lyon: IARC Scientific; 2002. Publication No.: 155
3. RP Beasley LY Hwang CC Lin CS Chien 1981 Hepatocellular carcinoma and hepatitis B virus. A prospective study of 22707 men in Taiwan Lancet 2 1129 1133 1:STN:280:DyaL38%2FnvFGktg%3D%3D 6118576
4. H Tsukuma T Hiyama S Tanaka M Nakao T Yabuuchi T Kitamura, et al. 1993 Risk factors for hepatocellular carcinoma among patients with chronic liver disease N Engl J Med 328 1797 1801 1:STN:280:DyaK3s3nsFektg%3D%3D 7684822 (Pubitemid 23174709)
5. CJ Chen KY Liang AS Chang YC Chang SN Lu YF Liaw, et al. 1991 Effects of hepatitis B virus, alcohol drinking, cigarette smoking and familial tendency on hepatocellular carcinoma Hepatology 13 398 406 1:STN:280:DyaK3M7ltlOlsQ%3D%3D 1847891
6. HI Yang SN Lu YF Liaw SL You CA Sun LY Wang, et al. 2002 Hepatitis B e antigen and the risk of hepatocellular carcinoma N Engl J Med 347 168 174 1:CAS:528:DC%2BD38Xlt12jsLw%3D 12124405
7. JF Tsai JE Jeng MS Ho WY Chang MY Hsieh ZY Lin, et al. 1996 Additive effect modification of hepatitis B surface antigen and e antigen on the development of hepatocellular carcinoma Br J Cancer 73 1498 1502 1:STN:280:DyaK283mt1Wgsg%3D%3D 8664119
8. SN Lu TM Lin CJ Chen JS Chen YF Liaw WY Chang, et al. 1988 A case-control study of primary hepatocellular carcinoma in Taiwan Cancer 62 2051 2055 1:STN:280:DyaL1M%2Fgt1KqsQ%3D%3D 2844388
9. TM Lin CJ Chen SN Lu AS Chang YC Chang ST Hsu, et al. 1991 Hepatitis B virus e antigen and primary hepatocellular carcinoma Anticancer Res 11 2063 2065 1:STN:280:DyaK387jsVSisQ%3D%3D 1663719
10. MW Yu SH Yeh PJ Chen YF Liaw CL Lin CJ Liu, et al. 2005 Hepatitis B virus genotype and DNA level and hepatocellular carcinoma: a prospective study in men J Natl Cancer Inst 97 265 272 1:CAS:528:DC%2BD2MXhsFSns78%3D 15713961
11. HL Chan CH Tse F Mo J Koh VW Wong GL Wong, et al. 2008 High viral load and hepatitis B virus subgenotype Ce are associated with increased risk of hepatocellular carcinoma J Clin Oncol 26 177 182 1:CAS:528:DC%2BD1cXitVWitr8%3D 18182659
12. CJ Chen HI Yang J Su CL Jen SL You SN Lu, et al. 2006 Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level JAMA 295 65 73 1:CAS:528:DC%2BD28XhtlKqtQ%3D%3D 16391218
13. G Chen W Lin F Shen UH Iloeje WT London AA Evans 2006 Past HBV viral load as predictor of mortality and morbidity from HCC and chronic liver disease in a prospective study Am J Gastroenterol 101 1797 1803 16817842
14. H Ding M Kudo H Onda Y Suetomi Y Minami H Chung, et al. 2001 Evaluation of posttreatment response of hepatocellular carcinoma with contrast-enhanced coded phase-inversion harmonic US: comparison with dynamic CT Radiology 221 721 730 1:STN:280:DC%2BD3MnntlOqtw%3D%3D 11719668
15. HI Yang SH Yeh PJ Chen UH Iloeje CL Jen J Su, et al. 2008 Associations between hepatitis B virus genotype and mutants and the risk of hepatocellular carcinoma J Natl Cancer Inst 100 1134 1143 1:CAS:528:DC%2BD1cXhtFKrsb7P 18695135
16. MF Yuen E Sablon HJ Yuan DK Wong CK Hui BC Wong, et al. 2003 Significance of hepatitis B genotype in acute exacerbation, HBeAg seroconversion, cirrhosis-related complications, and hepatocellular carcinoma Hepatology 37 562 567 12601354
17. JH Kao PJ Chen MY Lai DS Chen 2000 Hepatitis B genotypes correlate with clinical outcomes in patients with chronic hepatitis B Gastroenterology 118 554 559 1:STN:280:DC%2BD3c7mslWjug%3D%3D 10702206
18. H Sumi O Yokosuka N Seki M Arai F Imazeki T Kurihara, et al. 2003 Influence of hepatitis B virus genotypes on the progression of chronic type B liver disease Hepatology 37 19 26 1:CAS:528:DC%2BD3sXovVWitg%3D%3D 12500184
19. E Orito M Mizokami H Sakugawa K Michitaka K Ishikawa T Ichida, et al. 2001 A case-control study for clinical and molecular biological differences between hepatitis B viruses of genotypes B and C. Japan HBV Genotype Research Group Hepatology 33 218 223 1:CAS:528:DC%2BD3MXktFajsA%3D%3D 11124839
20. ZL Fang J Yang X Ge H Zhuang J Gong R Li, et al. 2002 Core promoter mutations (A(1762)T and G(1764)A) and viral genotype in chronic hepatitis B and hepatocellular carcinoma in Guangxi, China J Med Virol 68 33 40 1:CAS:528:DC%2BD38XmsFahsbc%3D 12210428
21. HE Chiou TE Wang YY Wang HW Liu 2006 Efficacy and safety of thalidomide in patients with hepatocellular carcinoma World J Gastroenterol 12 6955 6960 1:CAS:528:DC%2BD28XhtlGhsr%2FE 17109516
22. BF Chen CJ Liu GM Jow PJ Chen JH Kao DS Chen 2006 High prevalence and mapping of pre-S deletion in hepatitis B virus carriers with progressive liver diseases Gastroenterology 130 1153 1168 1:CAS:528:DC%2BD28XksFWmurY%3D 16618410
23. CH Chen CH Hung CM Lee TH Hu JH Wang JC Wang, et al. 2007 Pre-S deletion and complex mutations of hepatitis B virus related to advanced liver disease in HBeAg-negative patients Gastroenterology 133 1466 1474 1:CAS:528: DC%2BD2sXhsVGqtrzI 17915220
24. YC Chou MW Yu CF Wu SY Yang CL Lin CJ Liu, et al. 2008 Temporal relationship between hepatitis B virus enhancer II/basal core promoter sequence variation and risk of hepatocellular carcinoma Gut 57 91 97 1:CAS:528: DC%2BD1cXitVKqtrc%3D 17502344
25. JH Kao PJ Chen MY Lai DS Chen 2003 Basal core promoter mutations of hepatitis B virus increase the risk of hepatocellular carcinoma in hepatitis B carriers Gastroenterology 124 327 334 1:CAS:528:DC%2BD3sXhsFOhtbk%3D 12557138
26. G Fattovich G Giustina F Degos F Tremolada G Diodati P Almasio, et al. 1997 Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients Gastroenterology 112 463 472 1:STN:280:DyaK2s7ns1Olsw%3D%3D 9024300
27. F Tradati M Colombo PM Mannucci MG Rumi C De Fazio G Gamba, et al. 1998 A prospective multicenter study of hepatocellular carcinoma in Italian hemophiliacs with chronic hepatitis C. The Study Group of the Association of Italian Hemophilia Centers Blood 91 1173 1177 1:CAS:528:DyaK1cXhtVGksr8%3D 9454746
28. S Takano O Yokosuka F Imazeki M Tagawa M Omata 1995 Incidence of hepatocellular carcinoma in chronic hepatitis B and C: a prospective study of 251 patients Hepatology 21 650 655 1:STN:280:DyaK2M7otVyhsA%3D%3D 7875662
29. CA Sun DM Wu CC Lin SN Lu SL You LY Wang, et al. 2003 Incidence and cofactors of hepatitis C virus-related hepatocellular carcinoma: a prospective study of 12,008 men in Taiwan Am J Epidemiol 157 674 682 12697571
30. L Serfaty H Aumaitre O Chazouilleres AM Bonnand O Rosmorduc RE Poupon, et al. 1998 Determinants of outcome of compensated hepatitis C virus-related cirrhosis Hepatology 27 1435 1440 1:STN:280:DyaK1c3ktVygtw%3D%3D 9581703
31. C Niederau S Lange T Heintges A Erhardt M Buschkamp D Hurter, et al. 1998 Prognosis of chronic hepatitis C: results of a large, prospective cohort study Hepatology 28 1687 1695 1:STN:280:DyaK1M%2FkslGitQ%3D%3D 9828236
32. G Fattovich ML Ribero M Pantalena G Diodati P Almasio F Nevens, et al. 2001 Hepatitis C virus genotypes: distribution and clinical significance in patients with cirrhosis type C seen at tertiary referral centres in Europe J Viral Hepat 8 206 216 1:STN:280:DC%2BD3MzmtVWqsg%3D%3D 11380799
33. S Bruno E Silini A Crosignani F Borzio G Leandro F Bono, et al. 1997 Hepatitis C virus genotypes and risk of hepatocellular carcinoma in cirrhosis: a prospective study Hepatology 25 754 758 1:STN:280:DyaK2s3gtFCntw%3D%3D 9049231
34. S Bruno A Crosignani P Maisonneuve S Rossi E Silini MU Mondelli 2007 Hepatitis C virus genotype 1b as a major risk factor associated with hepatocellular carcinoma in patients with cirrhosis: a seventeen-year prospective cohort study Hepatology 46 1350 1356 1:CAS:528:DC%2BD2sXhtlOiu7vL 17680653
35. WL Chuang WY Chang SN Lu WP Su ZY Lin SC Chen, et al. 1992 The role of hepatitis B and C viruses in hepatocellular carcinoma in a hepatitis B endemic area. A case-control study Cancer 69 2052 2054 1:STN:280:DyaK387otlSksw%3D%3D 1311978
36. M Chiaramonte T Stroffolini A Vian MA Stazi A Floreani U Lorenzoni, et al. 1999 Rate of incidence of hepatocellular carcinoma in patients with compensated viral cirrhosis Cancer 85 2132 2137 1:STN:280:DyaK1M3ls1KhsA%3D%3D 10326690
37. CJ Chen MW Yu YF Liaw 1997 Epidemiological characteristics and risk factors of hepatocellular carcinoma J Gastroenterol Hepatol 12 S294 S308 1:STN:280:DyaK1c%2FntFansw%3D%3D 9407350
38. MC Yu MJ Tong P Coursaget RK Ross S Govindarajan BE Henderson 1990 Prevalence of hepatitis B and C viral markers in black and white patients with hepatocellular carcinoma in the United States J Natl Cancer Inst 82 1038 1041 1:STN:280:DyaK3c3ntFamug%3D%3D 2161463
39. A Tagger F Donato ML Ribero R Chiesa G Portera U Gelatti, et al. 1999 Case-control study on hepatitis C virus (HCV) as a risk factor for hepatocellular carcinoma: the role of HCV genotypes and the synergism with hepatitis B virus and alcohol Brescia HCC Study. Int J Cancer 81 695 699 1:STN:280:DyaK1M3lvVOksg%3D%3D
40. E Kaklamani D Trichopoulos A Tzonou X Zavitsanos Y Koumantaki A Hatzakis, et al. 1991 Hepatitis B and C viruses and their interaction in the origin of hepatocellular carcinoma JAMA 265 1974 1976 1:STN:280:DyaK3M7nvVyktA%3D%3D 1848908
41. CL Thio EC Seaberg R Skolasky Jr J Phair B Visscher A Munoz, et al. 2002 HIV-1, hepatitis B virus, and risk of liver-related mortality in the Multicenter Cohort Study (MACS) Lancet 360 1921 1926 12493258
42. N Brau RK Fox P Xiao K Marks Z Naqvi LE Taylor, et al. 2007 Presentation and outcome of hepatocellular carcinoma in HIV-infected patients: a US-Canadian multicenter study J Hepatol 47 527 537 17692986
43. DM Parkin F Bray J Ferlay P Pisani 2005 Global cancer statistics, 2002 CA Cancer J Clin 55 74 108 15761078
44. Y Shiratori S Shiina M Imamura N Kato F Kanai T Okudaira, et al. 1995 Characteristic difference of hepatocellular carcinoma between hepatitis B- and C- viral infection in Japan Hepatology 22 1027 1033 1:STN:280: DyaK28%2FivFCjtA%3D%3D 7557847
45. CM Lee SN Lu CS Changchien CT Yeh TT Hsu JH Tang, et al. 1999 Age, gender, and local geographic variations of viral etiology of hepatocellular carcinoma in a hyperendemic area for hepatitis B virus infection Cancer 86 1143 1150 1:STN:280:DyaK1MvjvVCisA%3D%3D 10506697
46. SN Lu WW Su SS Yang TT Chang KS Cheng JC Wu, et al. 2006 Secular trends and geographic variations of hepatitis B virus and hepatitis C virus-associated hepatocellular carcinoma in Taiwan Int J Cancer 119 1946 1952 1:CAS:528:DC%2BD28Xps1Snsbk%3D 16708389
47. H Yoshida R Tateishi Y Arakawa M Sata S Fujiyama S Nishiguchi, et al. 2004 Benefit of interferon therapy in hepatocellular carcinoma prevention for individual patients with chronic hepatitis C Gut 53 425 430 1:CAS:528: DC%2BD2cXitlersLc%3D 14960528
48. MC Yu MJ Tong S Govindarajan BE Henderson 1991 Nonviral risk factors for hepatocellular carcinoma in a low-risk population, the non-Asians of Los Angeles County, California J Natl Cancer Inst 83 1820 1826 1:STN:280: DyaK38%2FnvFaqug%3D%3D 1660542
49. K Tanaka T Hirohata S Takeshita I Hirohata S Koga K Sugimachi T Kanematsu, et al. 1992 Hepatitis B virus, cigarette smoking and alcohol consumption in the development of hepatocellular carcinoma: a case-control study in Fukuoka, Japan Int J Cancer 51 509 514 1:CAS:528:DyaK3sXmslCrsLo%3D 1318264
50. AE Mohamed MC Kew HT Groeneveld 1992 Alcohol consumption as a risk factor for hepatocellular carcinoma in urban southern African blacks Int J Cancer 51 537 541 1:STN:280:DyaK383ptVKhsg%3D%3D 1318267
51. F Donato A Tagger U Gelatti G Parrinello P Boffetta A Albertini, et al. 2002 Alcohol and hepatocellular carcinoma: the effect of lifetime intake and hepatitis virus infections in men and women Am J Epidemiol 155 323 331 1:STN:280:DC%2BD387ltVOmtg%3D%3D 11836196
52. R Chiesa F Donato A Tagger M Favret ML Ribero G Nardi, et al. 2000 Etiology of hepatocellular carcinoma in Italian patients with and without cirrhosis Cancer Epidemiol Biomarkers Prev 9 213 216 1:STN:280: DC%2BD3c7mt1eisg%3D%3D 10698484
53. JS Wang T Huang J Su F Liang Z Wei Y Liang, et al. 2001 Hepatocellular carcinoma and aflatoxin exposure in Zhuqing Village, Fusui County, People's Republic of China Cancer Epidemiol Biomarkers Prev 10 143 146 1:STN:280:DC%2BD3M3ksVGgtA%3D%3D 11219772
54. CJ Chen LY Wang SN Lu MH Wu SL You YJ Zhang, et al. 1996 Elevated aflatoxin exposure and increased risk of hepatocellular carcinoma Hepatology 24 38 42 1:CAS:528:DyaK28XkvFSjsb0%3D 8707279
55. GS Qian RK Ross MC Yu JM Yuan YT Gao BE Henderson, et al. 1994 A follow-up study of urinary markers of aflatoxin exposure and liver cancer risk in Shanghai, People's Republic of China Cancer Epidemiol Biomarkers Prev 3 3 10 1:STN:280:DyaK2c7mtlSqtw%3D%3D 8118382
56. RK Ross JM Yuan MC Yu GN Wogan GS Qian JT Tu, et al. 1992 Urinary aflatoxin biomarkers and risk of hepatocellular carcinoma Lancet 339 943 946 1:STN:280:DyaK383islKjug%3D%3D 1348796
57. LY Wang M Hatch CJ Chen B Levin SL You SN Lu, et al. 1996 Aflatoxin exposure and risk of hepatocellular carcinoma in Taiwan Int J Cancer 67 620 625 1:STN:280:DyaK28zns1OktA%3D%3D 8782648
58. CL Chen HI Yang WS Yang CJ Liu PJ Chen SL You, et al. 2008 Metabolic factors and risk of hepatocellular carcinoma by chronic hepatitis B/C infection: a follow-up study in Taiwan Gastroenterology 135 111 121 1:CAS:528: DC%2BD1cXps1Wlt78%3D 18505690
59. WT London AA Evans K McGlynn K Buetow P An L Gao, et al. 1995 Viral, host and environmental risk factors for hepatocellular carcinoma: a prospective study in Haimen City, China Intervirology 38 155 161 1:STN:280: DyaK283nsVagtQ%3D%3D 8682610
60. AA Evans G Chen EA Ross FM Shen WY Lin WT London 2002 Eight-year follow-up of the 90,000-person Haimen City cohort: I. Hepatocellular carcinoma mortality, risk factors, and gender differences Cancer Epidemiol Biomarkers Prev 11 369 376 11927497
61. MW Yu HC Chang YF Liaw SM Lin SD Lee CJ Liu, et al. 2000 Familial risk of hepatocellular carcinoma among chronic hepatitis B carriers and their relatives J Natl Cancer Inst 92 1159 1164 1:STN:280:DC%2BD3cvlvFensg%3D%3D 10904089
62. RA Bradbear C Bain V Siskind FD Schofield S Webb EM Axelsen, et al. 1985 Cohort study of internal malignancy in genetic hemochromatosis and other chronic nonalcoholic liver diseases J Natl Cancer Inst 75 81 84 1:STN:280: DyaL2M3jvVGjuw%3D%3D 2989605
63. C Niederau R Fischer A Sonnenberg W Stremmel HJ Trampisch G Strohmeyer 1985 Survival and causes of death in cirrhotic and in noncirrhotic patients with primary hemochromatosis N Engl J Med 313 1256 1262 1:STN:280: DyaL28%2FktVansw%3D%3D 4058506
64. M Elmberg R Hultcrantz A Ekbom L Brandt S Olsson R Olsson, et al. 2003 Cancer risk in patients with hereditary hemochromatosis and in their first-degree relatives Gastroenterology 125 1733 1741 14724826 (Pubitemid 37500438)
65. DS Chen NH Hsu JL Sung TC Hsu ST Hsu YT Kuo, et al. 1987 A mass vaccination program in Taiwan against hepatitis B virus infection in infants of hepatitis B surface antigen-carrier mothers JAMA 257 2597 2603 1:STN:280:DyaL2s7pvFWhsA%3D%3D 3573257
66. HM Hsu DS Chen CH Chuang JC Lu DM Jwo CC Lee, et al. 1988 Efficacy of a mass hepatitis B vaccination program in Taiwan. Studies on 3464 infants of hepatitis B surface antigen-carrier mothers JAMA 260 2231 2235 1:STN:280:DyaL1M%2Fht1emsQ%3D%3D 2971827
67. HL Chen MH Chang YH Ni HY Hsu PI Lee CY Lee, et al. 1996 Seroepidemiology of hepatitis B virus infection in children: ten years of mass vaccination in Taiwan JAMA 276 906 908 1:STN:280:DyaK28zns1Olug%3D%3D 8782640
68. MH Chang WY Shau CJ Chen TC Wu MS Kong DC Liang, et al. 2000 Hepatitis B vaccination and hepatocellular carcinoma rates in boys and girls JAMA 284 3040 3042 1:STN:280:DC%2BD3M%2FotVKisQ%3D%3D 11122592
69. JH Kao DS Chen 2002 Recent updates in hepatitis vaccination and the prevention of hepatocellular carcinoma Int J Cancer 97 269 271 1:CAS:528:DC%2BD38XhvVWmuw%3D%3D 11774275
70. C Niederau T Heintges S Lange G Goldmann CM Niederau L Mohr, et al. 1996 Long-term follow-up of HBeAg-positive patients treated with interferon alfa for chronic hepatitis B N Engl J Med 334 1422 1427 1:STN:280:DyaK283hvVyhtw%3D%3D 8618580
71. SM Lin IS Sheen RN Chien CM Chu YF Liaw 1999 Long-term beneficial effect of interferon therapy in patients with chronic hepatitis B virus infection Hepatology 29 971 975 1:CAS:528:DyaK1MXhvFyjsb8%3D 10051505
72. GV Papatheodoridis E Manesis SJ Hadziyannis 2001 The long-term outcome of interferon-alpha treated and untreated patients with HBeAg-negative chronic hepatitis B J Hepatol 34 306 313 1:CAS:528:DC%2BD3MXislCksbo%3D 11281561
73. P Lampertico E Del Ninno M Vigano R Romeo MF Donato E Sablon, et al. 2003 Long-term suppression of hepatitis B e antigen-negative chronic hepatitis B by 24-month interferon therapy Hepatology 37 756 763 1:CAS:528:DC%2BD3sXjt1Wltbo%3D 12668967 (Pubitemid 36397385)
74. M van Zonneveld P Honkoop BE Hansen HG Niesters SD Murad RA de Man, et al. 2004 Long-term follow-up of alpha-interferon treatment of patients with chronic hepatitis B Hepatology 39 804 810 14999700
75. DT Lau J Everhart DE Kleiner Y Park J Vergalla P Schmid, et al. 1997 Long-term follow-up of patients with chronic hepatitis B treated with interferon alfa Gastroenterology 113 1660 1667 1:CAS:528:DyaK2sXnt1yhtr4%3D 9352870
76. MF Yuen CK Hui CC Cheng CH Wu YP Lai CL Lai 2001 Long-term follow-up of interferon alfa treatment in Chinese patients with chronic hepatitis B infection: the effect on hepatitis B e antigen seroconversion and the development of cirrhosis-related complications Hepatology 34 139 145 1:CAS:528:DC%2BD3MXltlKjsL4%3D 11431745
77. SM Lin ML Yu CM Lee RN Chien IS Sheen CM Chu, et al. 2007 Interferon therapy in HBeAg positive chronic hepatitis reduces progression to cirrhosis and hepatocellular carcinoma J Hepatol 46 45 52 1:CAS:528:DC%2BD28Xht1Krs7vK 17107734
78. A Craxi C Camma 2005 Prevention of hepatocellular carcinoma Clin Liver Dis 9 329 346 15831277
79. GT Strickland 2006 Liver disease in Egypt: hepatitis C superseded schistosomiasis as a result of iatrogenic and biological factors Hepatology 43 915 922 16628669
80. JA Davila RO Morgan Y Shaib KA McGlynn HB El-Serag 2004 Hepatitis C infection and the increasing incidence of hepatocellular carcinoma: a population-based study Gastroenterology 127 1372 1380 15521006
81. H Yoshizawa 2002 Hepatocellular carcinoma associated with hepatitis C virus infection in Japan: projection to other countries in the foreseeable future Oncology 62 Suppl 1 8 17 11868791
82. H Yoshizawa J Tanaka Y Miyakawa 2006 National prevention of hepatocellular carcinoma in Japan based on epidemiology of hepatitis C virus infection in the general population Intervirology 49 7 17 16166783
83. M Omata O Yokosuka S Takano N Kato K Hosoda F Imazeki, et al. 1991 Resolution of acute hepatitis C after therapy with natural beta interferon Lancet 338 914 915 1:STN:280:DyaK38%2Fhs1yksw%3D%3D 1681268
84. E Jaeckel M Cornberg H Wedemeyer T Santantonio J Mayer M Zankel, et al. 2001 Treatment of acute hepatitis C with interferon alfa-2b N Engl J Med 345 1452 1457 1:CAS:528:DC%2BD3MXovVaqs70%3D 11794193
85. S Nishiguchi T Kuroki S Nakatani H Morimoto T Takeda S Nakajima, et al. 1995 Randomised trial of effects of interferon-alpha on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis Lancet 346 1051 1055 1:CAS:528:DyaK2MXpsl2lurY%3D 7564784
86. S Nishiguchi S Shiomi S Nakatani T Takeda K Fukuda A Tamori, et al. 2001 Prevention of hepatocellular carcinoma in patients with chronic active hepatitis C and cirrhosis Lancet 357 196 197 1:STN:280:DC%2BD3M7kvFCitQ%3D%3D 11213099
87. G Mazzella E Accogli S Sottili D Festi M Orsini A Salzetta, et al. 1996 Alpha interferon treatment may prevent hepatocellular carcinoma in HCV-related liver cirrhosis J Hepatol 24 141 147 1:STN:280:DyaK2s%2FmtlKquw%3D%3D 8907566
88. H Yoshida Y Shiratori M Moriyama Y Arakawa T Ide M Sata, et al. 1999 Interferon therapy reduces the risk for hepatocellular carcinoma: national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. IHIT Study Group. Inhibition of Hepatocarcinogenesis by Interferon Therapy Ann Intern Med 131 174 181 1:CAS:528:DyaK1MXlsVCrtbo%3D 10428733
89. Y Shiratori Y Ito O Yokosuka F Imazeki R Nakata N Tanaka, et al. 2005 Antiviral therapy for cirrhotic hepatitis C: association with reduced hepatocellular carcinoma development and improved survival Ann Intern Med 142 105 114 1:CAS:528:DC%2BD2MXktVequ74%3D 15657158
90. G Fattovich G Giustina F Degos G Diodati F Tremolada F Nevens, et al. 1997 Effectiveness of interferon alfa on incidence of hepatocellular carcinoma and decompensation in cirrhosis type C. European Concerted Action on Viral Hepatitis (EUROHEP) J Hepatol 27 201 205 1:CAS:528:DyaK2sXltVOrsb8%3D 9252096
91. GV Papatheodoridis VC Papadimitropoulos SJ Hadziyannis 2001 Effect of interferon therapy on the development of hepatocellular carcinoma in patients with hepatitis C virus-related cirrhosis: a meta-analysis Aliment Pharmacol Ther 15 689 698 1:CAS:528:DC%2BD3MXjslCjsLY%3D 11328263
92. C Camma M Giunta P Andreone A Craxi 2001 Interferon and prevention of hepatocellular carcinoma in viral cirrhosis: an evidence-based approach J Hepatol 34 593 602 1:CAS:528:DC%2BD3MXjvVerur4%3D 11394661
93. Y Imai S Kawata S Tamura I Yabuuchi S Noda M Inada, et al. 1998 Relation of interferon therapy and hepatocellular carcinoma in patients with chronic hepatitis C. Osaka Hepatocellular Carcinoma Prevention Study Group Ann Intern Med 129 94 99 1:CAS:528:DyaK1cXlt1emsbk%3D 9669992
94. K Ikeda S Saitoh Y Arase K Chayama Y Suzuki M Kobayashi, et al. 1999 Effect of interferon therapy on hepatocellular carcinogenesis in patients with chronic hepatitis type C: a long-term observation study of 1,643 patients using statistical bias correction with proportional hazard analysis Hepatology 29 1124 1130 1:CAS:528:DyaK1MXisVKgsLk%3D 10094956
95. M Shindo A Ken T Okuno 1999 Varying incidence of cirrhosis and hepatocellular carcinoma in patients with chronic hepatitis C responding differently to interferon therapy Cancer 85 1943 1950 1:CAS:528: DyaK1MXjtVCqsrk%3D 10223234
96. Y Shiratori F Imazeki M Moriyama M Yano Y Arakawa O Yokosuka, et al. 2000 Histologic improvement of fibrosis in patients with hepatitis C who have sustained response to interferon therapy Ann Intern Med 132 517 524 1:CAS:528:DC%2BD3cXisF2qu7g%3D 10744587
97. ML Yu SM Lin WL Chuang CY Dai JH Wang SN Lu, et al. 2006 A sustained virological response to interferon or interferon/ribavirin reduces hepatocellular carcinoma and improves survival in chronic hepatitis C: a nationwide, multicentre study in Taiwan Antivir Ther 11 985 994 1:CAS:528:DC%2BD2sXhtF2qt74%3D 17302368
98. Y Saito H Saito S Tada N Nakamoto H Horikawa S Kurita, et al. 2005 Effect of long-term interferon therapy for refractory chronic hepatitis c: preventive effect on hepatocarcinogenesis Hepatogastroenterology 52 1491 1496 1:CAS:528:DC%2BD2MXhtFChtr3L 16201104 (Pubitemid 41391023)
99. Y Arase K Ikeda F Suzuki Y Suzuki M Kobayashi N Akuta, et al. 2007 Prolonged-interferon therapy reduces hepatocarcinogenesis in aged-patients with chronic hepatitis C J Med Virol 79 1095 1102 1:CAS:528:DC%2BD2sXotl2ktLc%3D 17597485
100. Lok AS, Seeff LB, Morgan TR, Di Bisceglie AM, Sterling RK, Curto TM, et al. Incidence of hepatocellular carcinoma and associated risk factors in hepatitis c-related advanced liver disease. Gastroenterology [Epub 2008]
101. GN Wogan 1992 Aflatoxins as risk factors for hepatocellular carcinoma in humans Cancer Res 52 2114s 2118s 1:CAS:528:DyaK38XhvV2itLs%3D 1311989
102. MC Yu JM Yuan 2004 Environmental factors and risk for hepatocellular carcinoma Gastroenterology 127 S72 S78 1:CAS:528:DC%2BD2cXhtVGmtb%2FM 15508106
103. RE Omer A Kuijsten AM Kadaru FJ Kok MO Idris IM El Khidir, et al. 2004 Population-attributable risk of dietary aflatoxins and hepatitis B virus infection with respect to hepatocellular carcinoma Nutr Cancer 48 15 21 15203373
104. C La Vecchia 2005 Coffee, liver enzymes, cirrhosis and liver cancer J Hepatol 42 444 446 1:CAS:528:DC%2BD2MXitFyrurY%3D 15763323
105. HO Adami AW Hsing JK McLaughlin D Trichopoulos D Hacker A Ekbom, et al. 1992 Alcoholism and liver cirrhosis in the etiology of primary liver cancer Int J Cancer 51 898 902 1:STN:280:DyaK38zkvVSmtw%3D%3D 1639537
106. H Kuper A Tzonou E Kaklamani CC Hsieh P Lagiou HO Adami, et al. 2000 Tobacco smoking, alcohol consumption and their interaction in the causation of hepatocellular carcinoma Int J Cancer 85 498 502 1:STN:280: DC%2BD3c7msVGltw%3D%3D 10699921
107. C La Vecchia E Negri L Cavalieri d'Oro S Franceschi 1998 Liver cirrhosis and the risk of primary liver cancer Eur J Cancer Prev 7 315 320 1:STN:280:DyaK1M%2FitlSltQ%3D%3D 9806120 (Pubitemid 28473983)
108. S Honjo S Kono MP Coleman K Shinchi Y Sakurai I Todoroki, et al. 2001 Coffee consumption and serum aminotransferases in middle-aged Japanese men J Clin Epidemiol 54 823 829 1:STN:280:DC%2BD3MvitVOhsg%3D%3D 11470392
109. N Nakanishi K Nakamura K Nakajima K Suzuki K Tatara 2000 Coffee consumption and decreased serum gamma-glutamyltransferase: a study of middle-aged Japanese men Eur J Epidemiol 16 419 423 1:STN:280: DC%2BD3cvks1SmsQ%3D%3D 10997828
110. CE Ruhl JE Everhart 2005 Coffee and caffeine consumption reduce the risk of elevated serum alanine aminotransferase activity in the United States Gastroenterology 128 24 32 1:CAS:528:DC%2BD2MXhtFahtrc%3D 15633120
111. K Poikolainen E Vartiainen 1997 Determinants of gamma- glutamyltransferase: positive interaction with alcohol and body mass index, negative association with coffee Am J Epidemiol 146 1019 1024 1:STN:280:DyaK1c%2Fot1SqtA%3D%3D 9420526
112. S Honjo S Kono MP Coleman K Shinchi Y Sakurai I Todoroki, et al. 1999 Coffee drinking and serum gamma-glutamyltransferase: an extended study of Self-Defense Officials of Japan Ann Epidemiol 9 325 331 1:STN:280: DC%2BD3cvptlaitQ%3D%3D 10976859 (Pubitemid 29289847)
113. K Tanaka S Tokunaga S Kono S Tokudome T Akamatsu T Moriyama, et al. 1998 Coffee consumption and decreased serum gamma-glutamyltransferase and aminotransferase activities among male alcohol drinkers Int J Epidemiol 27 438 443 1:STN:280:DyaK1czmtFGqug%3D%3D 9698132
114. F Bravi C Bosetti A Tavani V Bagnardi S Gallus E Negri, et al. 2007 Coffee drinking and hepatocellular carcinoma risk: a meta-analysis Hepatology 46 430 435 17580359
115. SC Larsson A Wolk 2007 Coffee consumption and risk of liver cancer: a meta-analysis Gastroenterology 132 1740 1745 17484871 (Pubitemid 46677953)
116. A Tamori D Habu S Shiomi S Kubo S Nishiguchi 2007 Potential role of vitamin K(2) as a chemopreventive agent against hepatocellular carcinoma Hepatol Res 37 Suppl 2 S303 S307 1:CAS:528:DC%2BD2sXhtlCns7bM 17877500
117. I Sakai S Hashimoto M Yoda T Hida S Ohsawa S Nakajo, et al. 1994 Novel role of vitamin K2: a potent inducer of differentiation of various human myeloid leukemia cell lines Biochem Biophys Res Commun 205 1305 1310 1:CAS:528:DyaK2MXivVWltLk%3D 7802663
118. T Miyakawa Y Kajiwara A Shirahata K Okamoto H Itoh K Ohsato 2000 Vitamin K contents in liver tissue of hepatocellular carcinoma patients Jpn J Cancer Res 91 68 74 1:CAS:528:DC%2BD3cXitVWmu7s%3D 10744046
119. BI Carr Z Wang S Kar M Wang 1995 Prothrombin inhibits hepatocyte DNA synthesis (DNA-S) and expression of the a5 integrin gene Proc AACR 36 266
120. S Kar BI Carr 2000 Growth inhibition and protein tyrosine phosphorylation in MCF 7 breast cancer cells by a novel K vitamin J Cell Physiol 185 386 393 1:CAS:528:DC%2BD3cXnvVOhsb8%3D 11056008
121. BC Varnum C Young G Elliott A Garcia TD Bartley YW Fridell, et al. 1995 Axl receptor tyrosine kinase stimulated by the vitamin K-dependent protein encoded by growth-arrest-specific gene 6 Nature 373 623 626 1:CAS:528: DyaK2MXjsl2mtr4%3D 7854420
122. D Habu S Shiomi A Tamori T Takeda T Tanaka S Kubo, et al. 2004 Role of vitamin K2 in the development of hepatocellular carcinoma in women with viral cirrhosis of the liver JAMA 292 358 361 1:CAS:528:DC%2BD2cXlvFaju7c%3D 15265851
123. M Otsuka N Kato RX Shao Y Hoshida H Ijichi Y Koike, et al. 2004 Vitamin K2 inhibits the growth and invasiveness of hepatocellular carcinoma cells via protein kinase A activation Hepatology 40 243 251 1:CAS:528:DC%2BD2cXmtlSgurc%3D 15239108
124. T Mizuta I Ozaki Y Eguchi T Yasutake S Kawazoe K Fujimoto, et al. 2006 The effect of menatetrenone, a vitamin K2 analog, on disease recurrence and survival in patients with hepatocellular carcinoma after curative treatment: a pilot study Cancer 106 867 872 1:CAS:528:DC%2BD28XitVCrtLs%3D 16400650
125. N Hotta M Ayada K Sato T Ishikawa A Okumura E Matsumoto, et al. 2007 Effect of vitamin K2 on the recurrence in patients with hepatocellular carcinoma Hepatogastroenterology 54 2073 2077 1:CAS:528:DC%2BD1cXpvVWqsw%3D%3D 18251162
126. BR Bacon MJ Farahvash CG Janney BA Neuschwander-Tetri 1994 Nonalcoholic steatohepatitis: an expanded clinical entity Gastroenterology 107 1103 1109 1:STN:280:DyaK2M%2FhtFansw%3D%3D 7523217
127. CA Matteoni ZM Younossi T Gramlich N Boparai YC Liu AJ McCullough 1999 Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity Gastroenterology 116 1413 1419 1:STN:280:DyaK1M3nvVamtw%3D%3D 10348825
128. SH Caldwell DH Oelsner JC Iezzoni EE Hespenheide EH Battle CJ Driscoll 1999 Cryptogenic cirrhosis: clinical characterization and risk factors for underlying disease Hepatology 29 664 669 1:STN:280:DyaK1M7mt1emtw%3D%3D 10051466
129. A Cuadrado A Orive C Garcia-Suarez A Dominguez JC Fernandez-Escalante J Crespo, et al. 2005 Non-alcoholic steatohepatitis (NASH) and hepatocellular carcinoma Obes Surg 15 442 446 15826485
130. RT Wang RL Koretz HF Yee Jr 2003 Is weight reduction an effective therapy for nonalcoholic fatty liver? A systematic review Am J Med 115 554 559 14599635
131. HL Chan HJ de Silva NW Leung SG Lim GC Farrell 2007 How should we manage patients with non-alcoholic fatty liver disease in 2007? J Gastroenterol Hepatol 22 801 808 17565632
132. NC Chavez-Tapia T Barrientos-Gutierrez FI Tellez-Avila F Sanchez-Avila MA Montano-Reyes M Uribe 2006 Insulin sensitizers in treatment of nonalcoholic fatty liver disease: systematic review World J Gastroenterol 12 7826 7831 1:CAS:528:DC%2BD2sXhs12isLg%3D 17203528
133. G Strohmeyer C Niederau W Stremmel 1988 Survival and causes of death in hemochromatosis. Observations in 163 patients Ann N Y Acad Sci 526 245 257 1:STN:280:DyaL1c3mslOiuw%3D%3D 3389643
134. AW Hsing JK McLaughlin JH Olsen L Mellemkjar S Wacholder JF Fraumeni Jr 1995 Cancer risk following primary hemochromatosis: a population-based cohort study in Denmark Int J Cancer 60 160 162 1:STN:280:DyaK2M7jtVahtg%3D%3D 7829208
135. Q Yang SM McDonnell MJ Khoury J Cono RG Parrish 1998 Hemochromatosis- associated mortality in the United States from 1979 to 1992: an analysis of multiple-cause mortality data Ann Intern Med 129 946 953 1:STN:280: DyaK1M%2Fktlahuw%3D%3D 9867747
136. C Borgna-Pignatti G Vergine T Lombardo MD Cappellini P Cianciulli A Maggio, et al. 2004 Hepatocellular carcinoma in the thalassaemia syndromes Br J Haematol 124 114 117 14675416
137. E Mandishona AP MacPhail VR Gordeuk MA Kedda AC Paterson TA Rouault, et al. 1998 Dietary iron overload as a risk factor for hepatocellular carcinoma in black Africans Hepatology 27 1563 1566 1:STN:280:DyaK1c3otFKgtQ%3D%3D 9620327
138. KV Kowdley 2004 Iron, hemochromatosis, and hepatocellular carcinoma Gastroenterology 127 S79 S86 1:CAS:528:DC%2BD2cXhtVGmtb%2FN 15508107
139. BH Zhang BH Yang ZY Tang 2004 Randomized controlled trial of screening for hepatocellular carcinoma J Cancer Res Clin Oncol 130 417 422 15042359
140. MF Yuen Y Tanaka DY Fong J Fung DK Wong JC Yuen, et al. 2009 Independent risk factors and predictive score for the development of hepatocellular carcinoma in chronic hepatitis B J Hepatol 50 80 88 18977053
141. BJ McMahon L Bulkow A Harpster M Snowball A Lanier F Sacco, et al. 2000 Screening for hepatocellular carcinoma in Alaska natives infected with chronic hepatitis B: a 16-year population-based study Hepatology 32 842 846 1:STN:280:DC%2BD3cvpsFKltg%3D%3D 11003632
142. M Sherman KM Peltekian C Lee 1995 Screening for hepatocellular carcinoma in chronic carriers of hepatitis B virus: incidence and prevalence of hepatocellular carcinoma in a North American urban population Hepatology 22 432 438 1:STN:280:DyaK2Mzmt1WltA%3D%3D 7543434
143. AS Lok CL Lai 1989 alpha-Fetoprotein monitoring in Chinese patients with chronic hepatitis B virus infection: role in the early detection of hepatocellular carcinoma Hepatology 9 110 115 1:STN:280:DyaL1M%2FmsFGqtw%3D%3D 2461890
144. JR Bloomer TA Waldmann KR McIntire G Klatskin 1975 Alpha-fetoprotein in non-neoplastic hepatic disorders JAMA 233 38 41 1:STN:280:DyaE2M7nt1CgsQ%3D%3D 48562
145. E Alpert ER Feller 1978 Alpha-fetoprotein (AFP) in benign liver disease. Evidence that normal liver regeneration does not induce AFP synthesis Gastroenterology 74 856 858 1:CAS:528:DyaE1cXksFOktrc%3D 76587
146. J Ikoma M Kaito T Ishihara N Nakagawa A Kamei N Fujita, et al. 2002 Early diagnosis of hepatocellular carcinoma using a sensitive assay for serum des-gamma-carboxy prothrombin: a prospective study Hepatogastroenterology 49 235 238 1:CAS:528:DC%2BD38XjtFSns7g%3D 11941963
147. A Kasahara N Hayashi H Fusamoto Y Kawada Y Imai H Yamamoto, et al. 1993 Clinical evaluation of plasma des-gamma-carboxy prothrombin as a marker protein of hepatocellular carcinoma in patients with tumors of various sizes Dig Dis Sci 38 2170 2176 1:STN:280:DyaK2c%2FosFWhtQ%3D%3D 7505217 (Pubitemid 24035747)
148. A Maringhini M Cottone E Sciarrino MP Marceno F La Seta G Fusco, et al. 1988 Ultrasonography and alpha-fetoprotein in diagnosis of hepatocellular carcinoma in cirrhosis Dig Dis Sci 33 47 51 1:STN:280:DyaL1c7htV2itA%3D%3D 2448095
149. Y Mita Y Aoyagi M Yanagi T Suda Y Suzuki H Asakura 1998 The usefulness of determining des-gamma-carboxy prothrombin by sensitive enzyme immunoassay in the early diagnosis of patients with hepatocellular carcinoma Cancer 82 1643 1648 1:CAS:528:DyaK1cXivVyrs7w%3D 9576283
150. F Nomura M Ishijima A Horikoshi T Nakai K Ohnishi 1996 Determination of serum des-gamma-carboxy prothrombin levels in patients with small-sized hepatocellular carcinoma: comparison of the conventional enzyme immunoassay and two modified methods Am J Gastroenterol 91 1380 1383 1:STN:280: DyaK283otVGjuw%3D%3D 8677999
151. F Nomura M Ishijima K Kuwa N Tanaka T Nakai K Ohnishi 1999 Serum des-gamma-carboxy prothrombin levels determined by a new generation of sensitive immunoassays in patients with small-sized hepatocellular carcinoma Am J Gastroenterol 94 650 654 1:CAS:528:DyaK1MXitV2ku70%3D 10086646
152. H Oka A Saito K Ito T Kumada S Satomura H Kasugai, et al. 2001 Multicenter prospective analysis of newly diagnosed hepatocellular carcinoma with respect to the percentage of Lens culinaris agglutinin-reactive alpha-fetoprotein J Gastroenterol Hepatol 16 1378 1383 1:STN:280: DC%2BD387itVGqtw%3D%3D 11851836
153. T Suehiro K Sugimachi T Matsumata H Itasaka A Taketomi T Maeda 1994 Protein induced by vitamin K absence or antagonist II as a prognostic marker in hepatocellular carcinoma. Comparison with alpha-fetoprotein Cancer 73 2464 2471 1:STN:280:DyaK2c3ivVChug%3D%3D 7513601
154. Y Tanabe K Ohnishi F Nomura S Iida 1988 Plasma abnormal prothrombin levels in patients with small hepatocellular carcinoma Am J Gastroenterol 83 1386 1389 1:STN:280:DyaL1M%2FmtVaisA%3D%3D 2461655
155. KA Gebo G Chander MW Jenckes KG Ghanem HF Herlong MS Torbenson, et al. 2002 Screening tests for hepatocellular carcinoma in patients with chronic hepatitis C: a systematic review Hepatology 36 S84 S92 12407580
156. M Cottone M Turri M Caltagirone P Parisi A Orlando G Fiorentino, et al. 1994 Screening for hepatocellular carcinoma in patients with Child's A cirrhosis: an 8-year prospective study by ultrasound and alpha-fetoprotein J Hepatol 21 1029 1034 1:STN:280:DyaK2M3htlGnug%3D%3D 7535323
157. D Pateron N Ganne JC Trinchet MH Aurousseau F Mal C Meicler, et al. 1994 Prospective study of screening for hepatocellular carcinoma in Caucasian patients with cirrhosis J Hepatol 20 65 71 1:STN:280:DyaK2c3mtVSrsQ%3D%3D 7515408
158. L Irwig AN Tosteson C Gatsonis J Lau G Colditz TC Chalmers, et al. 1994 Guidelines for meta-analyses evaluating diagnostic tests Ann Intern Med 120 667 676 1:STN:280:DyaK2c7ot1ygtg%3D%3D 8135452
159. R Tateishi H Yoshida Y Matsuyama N Mine Y Kondo M Omata 2008 Diagnostic accuracy of tumor markers for hepatocellular carcinoma: a systematic review Hepatol Int 2 17 30 19669276
160. JA Marrero GL Su W Wei D Emick HS Conjeevaram RJ Fontana, et al. 2003 Des-gamma carboxyprothrombin can differentiate hepatocellular carcinoma from nonmalignant chronic liver disease in American patients Hepatology 37 1114 1121 1:CAS:528:DC%2BD3sXktVWnsLs%3D 12717392
161. R Cui J He F Zhang B Wang H Ding H Shen, et al. 2003 Diagnostic value of protein induced by vitamin K absence (PIVKAII) and hepatoma-specific band of serum gamma-glutamyl transferase (GGTII) as hepatocellular carcinoma markers complementary to alpha-fetoprotein Br J Cancer 88 1878 1882 1:CAS:528: DC%2BD3sXksVKjur4%3D 12799630
162. CS Wang CL Lin HC Lee KY Chen MF Chiang HS Chen, et al. 2005 Usefulness of serum des-gamma-carboxy prothrombin in detection of hepatocellular carcinoma World J Gastroenterol 11 6115 6119 1:CAS:528:DC%2BD28XhsVentLs%3D 16273636
163. RK Sterling L Jeffers F Gordon M Sherman AP Venook KR Reddy, et al. 2007 Clinical utility of AFP-L 3% measurement in North American patients with HCV-related cirrhosis Am J Gastroenterol 102 2196 2205 17617202
164. M Capurro IR Wanless M Sherman G Deboer W Shi E Miyoshi, et al. 2003 Glypican-3: a novel serum and histochemical marker for hepatocellular carcinoma Gastroenterology 125 89 97 1:CAS:528:DC%2BD3sXmtVWqtbk%3D 12851874
165. 2-terminal fragment of glypican-3 as a serological marker for early-stage hepatocellular carcinoma Cancer Res 64 2418 2423 1:CAS:528:DC%2BD2cXis1yjtLY%3D 15059894
166. MH Nguyen RT Garcia PW Simpson TL Wright EB Keeffe 2002 Racial differences in effectiveness of alpha-fetoprotein for diagnosis of hepatocellular carcinoma in hepatitis C virus cirrhosis Hepatology 36 410 417 1:CAS:528:DC%2BD38XmsVansLo%3D 12143050
167. M Soresi C Magliarisi P Campagna G Leto G Bonfissuto A Riili, et al. 2003 Usefulness of alpha-fetoprotein in the diagnosis of hepatocellular carcinoma Anticancer Res 23 1747 1753 1:CAS:528:DC%2BD2cXitVCgsLo%3D 12820452
168. O Arrieta B Cacho D Morales-Espinosa A Ruelas-Villavicencio D Flores-Estrada N Hernandez-Pedro 2007 The progressive elevation of alpha fetoprotein for the diagnosis of hepatocellular carcinoma in patients with liver cirrhosis BMC Cancer 7 28 17288606
169. SB Paul MS Gulati V Sreenivas K Madan AK Gupta S Mukhopadhyay 2007 Evaluating patients with cirrhosis for hepatocellular carcinoma: value of clinical symptomatology, imaging and alpha-fetoprotein Oncology 72 Suppl 1 117 123 18087192
170. Kew MC. Alpha-fetoprotein. In Read AE, editor. Modern Trends in Gastroenterology, vol. 5. London: Butterworths; 1975. p 91
171. HA Liebman BC Furie MJ Tong RA Blanchard KJ Lo SD Lee, et al. 1984 Des-gamma-carboxy (abnormal) prothrombin as a serum marker of primary hepatocellular carcinoma N Engl J Med 310 1427 1431 1:STN:280: DyaL2c7ptFersw%3D%3D 6201741
172. Y Koike Y Shiratori S Sato S Obi T Teratani M Imamura 2001 Yet al. Des-gamma-carboxy prothrombin as a useful predisposing factor for the development of portal venous invasion in patients with hepatocellular carcinoma: a prospective analysis of 227 patients Cancer 91 561 569 1:CAS:528: DC%2BD3MXhtVKjsLk%3D 11169939
173. H Imamura Y Matsuyama Y Miyagawa K Ishida R Shimada S Miyagawa, et al. 1999 Prognostic significance of anatomical resection and des-gamma-carboxy prothrombin in patients with hepatocellular carcinoma Br J Surg 86 1032 1038 1:STN:280:DyaK1MzptVagsg%3D%3D 10460639
174. Y Sato K Nakata Y Kato M Shima N Ishii T Koji, et al. 1993 Early recognition of hepatocellular carcinoma based on altered profiles of alpha-fetoprotein N Engl J Med 328 1802 1806 1:STN:280:DyaK3s3nsFektw%3D%3D 7684823
175. K Taketa Y Endo C Sekiya K Tanikawa T Koji H Taga, et al. 1993 A collaborative study for the evaluation of lectin-reactive alpha-fetoproteins in early detection of hepatocellular carcinoma Cancer Res 53 5419 5423 1:CAS:528:DyaK2cXltFCjsg%3D%3D 7693340
176. Y Aoyagi M Isemura Z Yosizawa Y Suzuki C Sekine T Ono, et al. 1985 Fucosylation of serum alpha-fetoprotein in patients with primary hepatocellular carcinoma Biochim Biophys Acta 830 217 223 1:CAS:528:DyaL2MXlslKgtLo%3D 2411292
177. HC Hsu W Cheng PL Lai 1997 Cloning and expression of a developmentally regulated transcript MXR7 in hepatocellular carcinoma: biological significance and temporospatial distribution Cancer Res 57 5179 5184 1:CAS:528: DyaK2sXnsV2kur8%3D 9371521
178. ZW Zhu H Friess L Wang M Abou-Shady A Zimmermann AD Lander, et al. 2001 Enhanced glypican-3 expression differentiates the majority of hepatocellular carcinomas from benign hepatic disorders Gut 48 558 564 1:CAS:528: DC%2BD3MXislyhurc%3D 11247902
179. T Sassa T Kumada S Nakano T Uematsu 1999 Clinical utility of simultaneous measurement of serum high-sensitivity des-gamma-carboxy prothrombin and Lens culinaris agglutinin A-reactive alpha-fetoprotein in patients with small hepatocellular carcinoma Eur J Gastroenterol Hepatol 11 1387 1392 1:CAS:528:DC%2BD3cXhtFSjtrw%3D 10654799
180. S Tanaka T Kitamura M Fujita K Nakanishi S Okuda 1990 Color Doppler flow imaging of liver tumors AJR Am J Roentgenol 154 509 514 1:STN:280: DyaK3c7msVeisA%3D%3D 2154912
181. S Tanaka T Kitamra M Fujita H Kasugai A Inoue S Ishiguro 1992 Small hepatocellular carcinoma: differentiation from adenomatous hyperplastic nodule with color Doppler flow imaging Radiology 182 161 165 1:STN:280: DyaK38%2FotVKqtw%3D%3D 1309217
182. JM Rubin RO Bude PL Carson RL Bree RS Adler 1994 Power Doppler US: a potentially useful alternative to mean frequency-based color Doppler US Radiology 190 853 856 1:STN:280:DyaK2c7lvFyrtA%3D%3D 8115639
183. K Koito T Namieno K Morita 1998 Differential diagnosis of small hepatocellular carcinoma and adenomatous hyperplasia with power Doppler sonography AJR Am J Roentgenol 170 157 161 1:STN:280:DyaK1c%2FosFKrsA%3D%3D 9423624
184. M Fujimoto F Moriyasu K Nishikawa T Nada M Okuma 1994 Color Doppler sonography of hepatic tumors with a galactose-based contrast agent: correlation with angiographic findings AJR Am J Roentgenol 163 1099 1104 1:STN:280:DyaK2M%2FmslCltw%3D%3D 7976882
185. H Ding M Kudo H Onda Y Suetomi Y Minami K Maekawa 2001 Hepatocellular carcinoma: depiction of tumor parenchymal flow with intermittent harmonic power Doppler US during the early arterial phase in dual-display mode Radiology 220 349 356 1:STN:280:DC%2BD3MvivFSnsw%3D%3D 11477236
186. M Kudo S Tomita H Tochio J Mimura Y Okabe H Kashida, et al. 1992 Sonography with intraarterial infusion of carbon dioxide microbubbles (sonographic angiography): value in differential diagnosis of hepatic tumors AJR Am J Roentgenol 158 65 74 1:STN:280:DyaK38%2FotFGmsw%3D%3D 1309220
187. K Yanagisawa F Moriyasu T Miyahara M Yuki H Iijima 2007 Phagocytosis of ultrasound contrast agent microbubbles by Kupffer cells Ultrasound Med Biol 33 318 325 17207907
188. M D'Onofrio E Martone N Faccioli G Zamboni R Malago RP Mucelli 2006 Focal liver lesions: sinusoidal phase of CEUS Abdom Imaging 31 529 536 16802201
189. K Hatanaka M Kudo Y Minami T Ueda C Tatsumi S Kitai, et al. 2008 Differential diagnosis of hepatic tumors: value of contrast-enhanced harmonic sonography using the newly developed contrast agent, Sonazoid Intervirology 51 Suppl 1 61 69 18544950
190. N Chalasani A Said R Ness H Hoen L Lumeng 1999 Screening for hepatocellular carcinoma in patients with cirrhosis in the United States: results of a national survey Am J Gastroenterol 94 2224 2229 1:STN:280:DyaK1Mznt1OhtA%3D%3D 10445554
191. J Collier M Sherman 1998 Screening for hepatocellular carcinoma Hepatology 27 273 278 1:STN:280:DyaK1c%2FosF2itA%3D%3D 9425947
192. K Kobayashi T Sugimoto H Makino M Kumagai M Unoura N Tanaka, et al. 1985 Screening methods for early detection of hepatocellular carcinoma Hepatology 5 1100 1105 1:STN:280:DyaL28%2FlslChsA%3D%3D 2998963
193. MP Federle 2002 Use of radiologic techniques to screen for hepatocellular carcinoma J Clin Gastroenterol 35 S92 S100 12394212
194. J Bruix M Sherman 2005 Practice Guidelines Committee, American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma Hepatology 42 1208 1236 16250051
195. S Saab D Ly J Nieto F Kanwal D Lu S Raman, et al. 2003 Hepatocellular carcinoma screening in patients waiting for liver transplantation: a decision analytic model Liver Transpl 9 672 681 12827551
196. M Burrel JM Llovet C Ayuso C Iglesias M Sala R Miquel, et al. 2003 MRI angiography is superior to helical CT for detection of HCC prior to liver transplantation: an explant correlation Hepatology 38 1034 1042 14512891
197. DH Van Thiel S Yong SD Li M Kennedy J Brems 2004 The development of de novo hepatocellular carcinoma in patients on a liver transplant list: frequency, size, and assessment of current screening methods Liver Transpl 10 631 637 15108254
198. HB El-Serag JA Marrero L Rudolph KR Reddy 2008 Diagnosis and treatment of hepatocellular carcinoma Gastroenterology 134 1752 1763 18471552
199. MR Arguedas VK Chen MA Eloubeidi MB Fallon 2003 Screening for hepatocellular carcinoma in patients with hepatitis C cirrhosis: a cost-utility analysis Am J Gastroenterol 98 679 690 12650806
200. TK Kim HJ Jang SR Wilson 2005 Imaging diagnosis of hepatocellular carcinoma with differentiation from other pathology Clin Liver Dis 9 253 279 15831272
201. O Matsui 2004 Imaging of multistep human hepatocarcinogenesis by CT during intra-arterial contrast injection Intervirology 47 271 276 15383735
202. JA Marrero HK Hussain HV Nghiem R Umar RJ Fontana AS Lok 2005 Improving the prediction of hepatocellular carcinoma in cirrhotic patients with an arterially-enhancing liver mass Liver Transpl 11 281 289 15719410
203. A Colli M Fraquelli G Casazza S Massironi A Colucci D Conte, et al. 2006 Accuracy of ultrasonography, spiral CT, magnetic resonance, and alpha-fetoprotein in diagnosing hepatocellular carcinoma: a systematic review Am J Gastroenterol 101 513 523 1:CAS:528:DC%2BD28XjtlGhsLs%3D 16542288
204. SH Kim BI Choi JY Lee SJ Kim YH So HW Eun 2008 Diagnostic accuracy of multi-/single-detector row CT and contrast-enhanced MRI in the detection of hepatocellular carcinomas meeting the Milan criteria before liver transplantation Intervirology 51 Suppl 1 52 60 18544949
205. JM Willatt HK Hussain S Adusumilli JA Marrero 2008 MR Imaging of hepatocellular carcinoma in the cirrhotic liver: challenges and controversies Radiology 247 311 330 18430871
206. M Ebara M Ohto Y Watanabe K Kimura H Saisho Y Tsuchiya, et al. 1986 Diagnosis of small hepatocellular carcinoma: correlation of MR imaging and tumor histologic studies Radiology 159 371 377 1:STN:280:DyaL287nvVCisQ%3D%3D 3008213
207. A Rode B Bancel P Douek M Chevallier V Vilgrain G Picaud, et al. 2001 Small nodule detection in cirrhotic livers: evaluation with US, spiral CT, and MRI and correlation with pathologic examination of explanted liver J Comput Assist Tomogr 25 327 336 1:STN:280:DC%2BD3M3ls1SgtA%3D%3D 11351179
208. GA Krinsky VS Lee ND Theise JC Weinreb NM Rofsky T Diflo, et al. 2001 Hepatocellular carcinoma and dysplastic nodules in patients with cirrhosis: prospective diagnosis with MR imaging and explantation correlation Radiology 219 445 454 1:STN:280:DC%2BD3M3mt1eisg%3D%3D 11323471
209. RL Baron MS Peterson 2001 From the RSNA refresher courses: screening the cirrhotic liver for hepatocellular carcinoma with CT and MR imaging: opportunities and pitfalls Radiographics 21 S117 S132 11598252
210. AE Holland EM Hecht WY Hahn DC Kim JS Babb VS Lee, et al. 2005 Importance of small (≥20-mm) enhancing lesions seen only during the hepatic arterial phase at MR imaging of the cirrhotic liver: evaluation and comparison with whole explanted liver Radiology 237 938 944 16306035
211. G Brancatelli RL Baron MS Peterson W Marsh 2003 Helical CT screening for hepatocellular carcinoma in patients with cirrhosis: frequency and causes of false-positive interpretation AJR Am J Roentgenol 180 1007 1014 12646446
212. JM Llovet A Burroughs J Bruix 2003 Hepatocellular carcinoma Lancet 362 1907 1917 14667750
213. S Arii Y Yamaoka S Futagawa K Inoue K Kobayashi M Kojiro, et al. 2000 Results of surgical and nonsurgical treatment for small-sized hepatocellular carcinomas: a retrospective and nationwide survey in Japan. The Liver Cancer Study Group of Japan Hepatology 32 1224 1229 1:STN:280:DC%2BD3M%2FntFegsQ%3D%3D 11093728
214. YK Kim HS Kwak CS Kim GH Chung YM Han JM Lee 2006 Hepatocellular carcinoma in patients with chronic liver disease: comparison of SPIO-enhanced MR imaging and 16-detector row CT Radiology 238 531 541 16371577
215. B Bhartia J Ward JA Guthrie PJ Robinson 2003 Hepatocellular carcinoma in cirrhotic livers: double-contrast thin-section MR imaging with pathologic correlation of explanted tissue AJR Am J Roentgenol 180 577 584 12591657
216. J Ward JA Guthrie DJ Scott J Atchley D Wilson MH Davies, et al. 2000 Hepatocellular carcinoma in the cirrhotic liver: double-contrast MR imaging for diagnosis Radiology 216 154 162 1:STN:280:DC%2BD3czksl2ltA%3D%3D 10887242
217. HJ Yoo JM Lee MW Lee SJ Kim JY Lee JK Han 2008 et al. Hepatocellular carcinoma in cirrhotic liver: double-contrast-enhanced, high-resolution 3.0T-MR imaging with pathologic correlation Invest Radiol 43 538 546 18580337
218. K Mori H Yoshioka Y Itai Y Okamoto H Mori N Takahashi, et al. 2000 Arterioportal shunts in cirrhotic patients: evaluation of the difference between tumorous and nontumorous arterioportal shunts on MR imaging with superparamagnetic iron oxide AJR Am J Roentgenol 175 1659 1664 1:STN:280:DC%2BD3M%2FnsFGmuw%3D%3D 11090400
219. SH Choi JM Lee NC Yu KS Suh JJ Jang SH Kim, et al. 2008 Hepatocellular carcinoma in liver transplantation candidates: detection with gadobenate dimeglumine-enhanced MRI AJR Am J Roentgenol 191 529 536 18647927
220. M Sakamoto S Hirohashi Y Shimosato 1991 Early stages of multistep hepatocarcinogenesis: adenomatous hyperplasia and early hepatocellular carcinoma Hum Pathol 22 172 178 1:STN:280:DyaK3M7mtFWmsg%3D%3D 1848205
221. M Sakamoto S Hirohashi 1998 Natural history and prognosis of adenomatous hyperplasia and early hepatocellular carcinoma: multi-institutional analysis of 53 nodules followed up for more than 6 months and 141 patients with single early hepatocellular carcinoma treated by surgical resection or percutaneous ethanol injection Jpn J Clin Oncol 28 604 608 1:STN:280:DyaK1M%2Fltlagtw%3D%3D 9839500
222. M Kojiro 2004 Focus on dysplastic nodules and early hepatocellular carcinoma: an Eastern point of view Liver Transpl 10 S3 S8 14762831
223. L Bolondi S Gaiani N Celli R Golfieri WF Grigioni S Leoni, et al. 2005 Characterization of small nodules in cirrhosis by assessment of vascularity: the problem of hypovascular hepatocellular carcinoma Hepatology 42 27 34 15954118
224. M Kudo T Okanoue 2007 Management of hepatocellular carcinoma in Japan: consensus-based clinical practice manual proposed by the Japan Society of Hepatology Oncology 72 Suppl 1 2 15 18087177
225. Y Imai T Murakami S Yoshida M Nishikawa M Ohsawa K Tokunaga, et al. 2000 Superparamagnetic iron oxide-enhanced magnetic resonance images of hepatocellular carcinoma: correlation with histological grading Hepatology 32 205 212 1:STN:280:DC%2BD3cvgsVWntA%3D%3D 10915725
226. JH Lim D Choi SK Cho SH Kim WJ Lee HK Lim, et al. 2001 Conspicuity of hepatocellular nodular lesions in cirrhotic livers at ferumoxides-enhanced MR imaging: importance of Kupffer cell number Radiology 220 669 676 1:STN:280:DC%2BD3MvosFemtA%3D%3D 11526265
227. JP Heiken PJ Weyman JK Lee DM Balfe D Picus EM Brunt, et al. 1989 Detection of focal hepatic masses: prospective evaluation with CT, delayed CT, CT during arterial portography, and MR imaging Radiology 171 47 51 1:STN:280:DyaL1M7osFGisA%3D%3D 2538862
228. M Kanematsu H Hoshi T Imaeda T Murakami Y Inaba R Yokoyama, et al. 1997 Detection and characterization of hepatic tumors: value of combined helical CT hepatic arteriography and CT during arterial portography AJR Am J Roentgenol 168 1193 1198 1:STN:280:DyaK2s3nsFKnsg%3D%3D 9129410
229. M Kanematsu H Hoshi T Murakami Y Inaba T Kim T Yamada, et al. 1997 Detection of hepatocellular carcinoma in patients with cirrhosis: MR imaging versus angiographically assisted helical CT AJR Am J Roentgenol 169 1507 1515 1:STN:280:DyaK1c%2FlsVyltg%3D%3D 9393154
230. D Choi S Kim J Lim W Lee H Jang S Lee, et al. 2001 Preoperative detection of hepatocellular carcinoma: ferumoxides-enhanced MR imaging versus combined helical CT during arterial portography and CT hepatic arteriography AJR Am J Roentgenol 176 475 482 1:STN:280:DC%2BD3M3isVajug%3D%3D 11159099 (Pubitemid 32105665)
231. 18F-fluorodeoxyglucose positron emission tomography in detecting extrahepatic metastasis in pretreatment staging of hepatocellular carcinoma Oncology 72 Suppl 1 104 110 18087190
232. SH Yang KS Suh HW Lee EH Cho JY Cho YB Cho, et al. 2006 The role of (18)F-FDG-PET imaging for the selection of liver transplantation candidates among hepatocellular carcinoma patients Liver Transpl 12 1655 1660 16964589
233. S Shiomi S Nishiguchi H Ishizu Y Iwata N Sasaki A Tamori, et al. 2001 Usefulness of positron emission tomography with fluorine-18-fluorodeoxyglucose for predicting outcome in patients with hepatocellular carcinoma Am J Gastroenterol 96 1877 1880 1:STN:280:DC%2BD3MzlvFWjsw%3D%3D 11419843
234. MA Khan CS Combs EM Brunt VJ Lowe MK Wolverson H Solomon, et al. 2000 Positron emission tomography scanning in the evaluation of hepatocellular carcinoma J Hepatol 32 792 797 1:STN:280:DC%2BD3cvnt12ntg%3D%3D 10845666
235. J Trojan O Schroeder J Raedle RP Baum G Herrmann V Jacobi, et al. 1999 Fluorine-18 FDG positron emission tomography for imaging of hepatocellular carcinoma Am J Gastroenterol 94 3314 3319 1:STN:280:DC%2BD3c%2FjtFSisA%3D%3D 10566736
236. 18F-FDG PET in the detection of extrahepatic metastases from hepatocellular carcinoma J Gastroenterol 39 961 968 1:CAS:528: DC%2BD2cXpt1ehsr8%3D 15549449
237. A Tanimoto G Wakabayashi H Shinmoto S Nakatsuka S Okuda S Kuribayashi 2005 Superparamagnetic iron oxide-enhanced MR imaging for focal hepatic lesions: a comparison with CT during arterioportography plus CT during hepatic arteriography J Gastroenterol 40 371 380 15870974
238. Kojiro M. Pathology of hepatocellular carcinoma. In Okuda K, Tabor E, editors. Liver Cancer. New York: Churchill Livingstone; 1997. p. 165-187
239. T Tajima H Honda K Taguchi Y Asayama T Kuroiwa K Yoshimitsu, et al. 2002 Sequential hemodynamic change in hepatocellular carcinoma and dysplastic nodules: CT angiography and pathologic correlation AJR Am J Roentgenol 178 885 897 11906868
240. M Hayashi O Matsui K Ueda Y Kawamori T Gabata M Kadoya 2002 Progression to hypervascular hepatocellular carcinoma: correlation with intranodular blood supply evaluated with CT during intraarterial injection of contrast material Radiology 225 143 149 12354998
241. M Kudo 1999 Imaging diagnosis of hepatocellular carcinoma and premalignant/borderline lesions Semin Liver Dis 19 297 309 1:STN:280: DyaK1Mvks1GktQ%3D%3D 10518309
242. H Ding M Kudo H Onda Y Suetomi Y Minami K Maekawa 2001 Contrast-enhanced subtraction harmonic sonography for evaluating treatment response in patients with hepatocellular carcinoma AJR Am J Roentgenol 176 661 666 1:STN:280:DC%2BD3M3is1Kktw%3D%3D 11222201
243. YL Wen M Kudo RQ Zheng H Ding P Zhou Y Minami, et al. 2004 Characterization of hepatic tumors: value of contrast-enhanced coded phase-inversion harmonic angio AJR Am J Roentgenol 182 1019 1026 15039180
244. Y Asahina N Izumi M Uchihara O Noguchi K Ueda K Inoue, et al. 2003 Assessment of Kupffer cells by ferumoxides-enhanced MR imaging is beneficial for diagnosis of hepatocellular carcinoma: comparison of pathological diagnosis and perfusion patterns assessed by CT hepatic arteriography and CT arterioportography Hepatol Res 27 196 204 14585396
245. EA Akriviadis JM Llovet SC Efremidis D Shouval R Canelo B Ringe, et al. 1998 Hepatocellular carcinoma Br J Surg 85 1319 1331 1:STN:280: DyaK1cvltlaksg%3D%3D 9782009
246. J Bruix JM Llovet 2002 Prognostic prediction and treatment strategy in hepatocellular carcinoma Hepatology 35 519 524 11870363
247. JM Regimbeau O Farges BY Shen A Sauvanet J Belghiti 1999 Is surgery for large hepatocellular carcinoma justified? J Hepatol 31 1062 1068 1:STN:280:DC%2BD3c%2FmvVSrsg%3D%3D 10604580
248. RT Poon ST Fan J Wong 2002 Selection criteria for hepatic resection in patients with large hepatocellular carcinoma larger than 10 cm in diameter J Am Coll Surg 194 592 602 12022599
249. KK Ng JN Vauthey TM Pawlik GY Lauwers JM Regimbeau J Belghiti, et al. 2005 Is hepatic resection for large or multinodular hepatocellular carcinoma justified? Results from a multi-institutional database Ann Surg Oncol 12 364 373 15915370
250. TM Pawlik RT Poon EK Abdalla I Ikai DM Nagorney J Belghiti, et al. 2005 Hepatectomy for hepatocellular carcinoma with major portal or hepatic vein invasion: results of a multicenter study Surgery 137 403 410 15800485
251. CL Liu ST Fan CM Lo IO Ng RT Poon J Wong 2003 Hepatic resection for bilobar hepatocellular carcinoma: is it justified? Arch Surg 138 100 104 12511161 (Pubitemid 36055659)
252. D Choi HK Lim JW Joh SJ Kim MJ Kim H Rhim, et al. 2007 Combined hepatectomy and radiofrequency ablation for multifocal hepatocellular carcinomas: long-term follow-up results and prognostic factors Ann Surg Oncol 14 3510 3518 17653800 (Pubitemid 350160100)
253. G Torzilli M Makuuchi K Inoue T Takayama Y Sakamoto Y Sugawara, et al. 1999 No-mortality liver resection for hepatocellular carcinoma in cirrhotic and noncirrhotic patients: is there a way? A prospective analysis of our approach Arch Surg 134 984 992 1:STN:280:DyaK1MvhsFGgtw%3D%3D 10487594
254. RT Poon ST Fan CM Lo CL Liu CM Lam WK Yuen, et al. 2004 Improving perioperative outcome expands the role of hepatectomy in management of benign and malignant hepatobiliary diseases: analysis of 1222 consecutive patients from a prospective database Ann Surg 240 698 708 15383797 discussion 708-710
255. B Asiyanbola D Chang AL Gleisner H Nathan MA Choti RD Schulick, et al. 2008 Operative mortality after hepatic resection: are literature-based rates broadly applicable? J Gastrointest Surg 12 842 851 18266046
256. FM Polignano AJ Quyn RS de Figueiredo NA Henderson C Kulli IS Tait 2008 Laparoscopic versus open liver segmentectomy: prospective, case-matched, intention-to-treat analysis of clinical outcomes and cost effectiveness Surg Endosc 22 2564 2570 18814007
257. GL Grazi G Ercolani F Pierangeli M Del Gaudio M Cescon A Cavallari, et al. 2001 Improved results of liver resection for hepatocellular carcinoma on cirrhosis give the procedure added value Ann Surg 234 71 78 1:STN:280: DC%2BD3MzlvFChtg%3D%3D 11420485
258. RT Poon ST Fan CM Lo IO Ng CL Liu CM Lam, et al. 2001 Improving survival results after resection of hepatocellular carcinoma: a prospective study of 377 patients over 10 years Ann Surg 234 63 70 1:STN:280:DC%2BD3MzlvFChsQ%3D%3D 11420484
259. L Capussotti A Muratore M Amisano R Polastri H Bouzari P Massucco 2005 Liver resection for hepatocellular carcinoma on cirrhosis: analysis of mortality, morbidity and survival-a European single center experience Eur J Surg Oncol 31 986 993 1:STN:280:DC%2BD2Mrpt1Ontw%3D%3D 15936169
260. RT Poon ST Fan CM Lo CL Liu J Wong 2007 Difference in tumor invasiveness in cirrhotic patients with hepatocellular carcinoma fulfilling the Milan criteria treated by resection and transplantation: impact on long-term survival Ann Surg 245 51 58 17197965
261. H Ishii J Furuse T Kinoshita M Konishi T Nakagohri S Takahashi, et al. 2008 Hepatectomy for hepatocellular carcinoma patients who meet the Milan criteria Hepatogastroenterology 55 621 626 18613420
262. RT Poon ST Fan IO Ng J Wong 2000 Significance of resection margin in hepatectomy for hepatocellular carcinoma: a critical reappraisal Ann Surg 231 544 551 1:STN:280:DC%2BD3c3htlahsg%3D%3D 10749616
263. S Yamazaki T Takayama 2008 Surgical treatment of hepatocellular carcinoma: evidence-based outcomes World J Gastroenterol 14 685 692 18205256
264. RT Poon ST Fan CM Lo CL Liu J Wong 1999 Intrahepatic recurrence after curative resection of hepatocellular carcinoma: long-term results of treatment and prognostic factors Ann Surg 229 216 222 1:STN:280:DyaK1M7ks1Ojug%3D%3D 10024103
265. I Penn 1991 Hepatic transplantation for primary and metastatic cancers of the liver Surgery 110 726 734 1:STN:280:DyaK38%2FitlShtg%3D%3D 1656538 discussion 734-5
266. V Mazzaferro E Regalia R Doci S Andreola A Pulvirenti F Bozzetti, et al. 1996 Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis N Engl J Med 334 693 699 1:STN:280: DyaK287nsFWltw%3D%3D 8594428
267. FY Yao L Ferrell NM Bass JJ Watson P Bacchetti A Venook, et al. 2001 Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival Hepatology 33 1394 1403 1:STN:280:DC%2BD3MzhvFajtQ%3D%3D 11391528
268. JA Fernandez R Robles C Marin F Sanchez-Bueno P Ramirez JA Pons, et al. 2003 Can we expand the indications for liver transplantation among hepatocellular carcinoma patients with increased tumor size? Transplant Proc 35 1818 1820 1:STN:280:DC%2BD3svitlCltQ%3D%3D 12962807
269. G Otto U Heuschen WJ Hofmann G Krumm U Hinz C Herfarth 1998 Survival and recurrence after liver transplantation versus liver resection for hepatocellular carcinoma: a retrospective analysis Ann Surg 227 424 432 1:STN:280: DyaK1c7os1aqtw%3D%3D 9527066
270. JM Llovet J Fuster J Bruix 1999 Intention-to-treat analysis of surgical treatment for early hepatocellular carcinoma: resection versus transplantation Hepatology 30 1434 1440 1:STN:280:DC%2BD3c%2Fkt1eiug%3D%3D 10573522
271. J Figueras L Ibanez E Ramos E Jaurrieta J Ortiz-de-Urbina F Pardo, et al. 2001 Selection criteria for liver transplantation in early-stage hepatocellular carcinoma with cirrhosis: results of a multicenter study Liver Transpl 7 877 883 1:STN:280:DC%2BD3MrntVGhtg%3D%3D 11679986
272. S Jonas WO Bechstein T Steinmuller M Herrmann C Radke T Berg, et al. 2001 Vascular invasion and histopathologic grading determine outcome after liver transplantation for hepatocellular carcinoma in cirrhosis Hepatology 33 1080 1086 1:STN:280:DC%2BD3MzgvFOluw%3D%3D 11343235
273. GB Klintmalm 1998 Liver transplantation for hepatocellular carcinoma: a registry report of the impact of tumor characteristics on outcome Ann Surg 228 479 490 1:STN:280:DyaK1M%2FgsV2qug%3D%3D 9790338
274. J Belghiti BI Carr PD Greig R Lencioni RT Poon 2008 Treatment before liver transplantation for HCC Ann Surg Oncol 15 993 1000 1:STN:280: DC%2BD1c7ntFOgtQ%3D%3D 18236111
275. JF Trotter M Wachs GT Everson I Kam 2002 Adult-to-adult transplantation of the right hepatic lobe from a living donor N Engl J Med 346 1074 1082 11932476
276. L Kulik M Abecassis 2004 Living donor liver transplantation for hepatocellular carcinoma Gastroenterology 127 S277 S282 15508095
277. RT Poon 2007 Optimal initial treatment for early hepatocellular carcinoma in patients with preserved liver function: transplantation or resection? Ann Surg Oncol 14 541 547 17103069
278. RT Poon ST Fan CM Lo CL Liu J Wong 2002 Long-term survival and pattern of recurrence after resection of small hepatocellular carcinoma in patients with preserved liver function: implications for a strategy of salvage transplantation Ann Surg 235 373 382 11882759
279. J Belghiti A Cortes EK Abdalla JM Regimbeau K Prakash F Durand, et al. 2003 Resection prior to liver transplantation for hepatocellular carcinoma Ann Surg 238 885 892 14631225 discussion 892-893
280. N Sugiura K Takara M Ohto K Okuda N Hirokawa 1983 Percutaneous intratumoral injection of ethanol under ultrasound imaging for treatment of small hepatocellular carcinoma Acta Hepatol Jpn 24 920
281. T Livraghi D Festi F Monti A Salmi C Vettori 1986 US-guided percutaneous alcohol injection of small hepatic and abdominal tumors Radiology 161 309 312 1:STN:280:DyaL2s%2FhslKrug%3D%3D 3020612
282. S Shiina H Yasuda H Muto K Tagawa T Unuma K Ibukuro, et al. 1987 Percutaneous ethanol injection in the treatment of liver neoplasms AJR Am J Roentgenol 149 949 952 1:STN:280:DyaL1c%2Fks1Cnsg%3D%3D 2823586
283. T Seki M Wakabayashi T Nakagawa T Itho T Shiro K Kunieda, et al. 1994 Ultrasonically guided percutaneous microwave coagulation therapy for small hepatocellular carcinoma Cancer 74 817 825 1:STN:280:DyaK2czhtlGhtg%3D%3D 8039109 (Pubitemid 24237460)
284. S Rossi M Di Stasi E Buscarini L Cavanna P Quaretti E Squassante, et al. 1995 Percutaneous radiofrequency interstitial thermal ablation in the treatment of small hepatocellular carcinoma Cancer J Sci Am 1 73 81 1:STN:280: DC%2BD28rmsFOqtg%3D%3D 9166457
285. T Livraghi SN Goldberg S Lazzaroni F Meloni L Solbiati GS Gazelle 1999 Small hepatocellular carcinoma: treatment with radio-frequency ablation versus ethanol injection Radiology 210 655 661 1:STN:280:DyaK1M3itlyksw%3D%3D 10207464
286. S Shiina T Teratani S Obi K Hamamura Y Koike M Omata 2002 Nonsurgical treatment of hepatocellular carcinoma: from percutaneous ethanol injection therapy and percutaneous microwave coagulation therapy to radiofrequency ablation Oncology 62 Suppl 1 64 68 1:CAS:528:DC%2BD38Xot1SnsQ%3D%3D 11868788
287. S Shiina K Tagawa Y Niwa T Unuma Y Komatsu K Yoshiura, et al. 1993 Percutaneous ethanol injection therapy for hepatocellular carcinoma: results in 146 patients AJR Am J Roentgenol 160 1023 1028 1:STN:280:DyaK3s3isl2mtw%3D%3D 7682378 (Pubitemid 23141242)
288. M Ebara S Okabe K Kita N Sugiura H Fukuda M Yoshikawa, et al. 2005 Percutaneous ethanol injection for small hepatocellular carcinoma: therapeutic efficacy based on 20-year observation J Hepatol 43 458 464 1:CAS:528: DC%2BD2MXntVCku7w%3D 16005538
289. YM Sung D Choi HK Lim WJ Lee SH Kim MJ Kim, et al. 2006 Long-term results of percutaneous ethanol injection for the treatment of hepatocellular carcinoma in Korea Korean J Radiol 7 187 192 16969048
290. I Ikai S Arii M Okazaki K Okita M Omata M Kojiro, et al. 2007 Report of the 17th nationwide follow-up survey of primary liver cancer in Japan Hepatol Res 37 676 691 17617112
291. T Livraghi A Giorgio G Marin A Salmi I de Sio L Bolondi, et al. 1995 Hepatocellular carcinoma and cirrhosis in 746 patients: long-term results of percutaneous ethanol injection Radiology 197 101 108 1:STN:280: DyaK28%2FitlWgsw%3D%3D 7568806
292. H Ishii S Okada H Nose T Okusaka M Yoshimori T Takayama, et al. 1996 Local recurrence of hepatocellular carcinoma after percutaneous ethanol injection Cancer 77 1792 1796 1:CAS:528:DyaK28XjtVGktLY%3D 8646676
293. M Di Stasi L Buscarini T Livraghi A Giorgio A Salmi I De Sio, et al. 1997 Percutaneous ethanol injection in the treatment of hepatocellular carcinoma. A multicenter survey of evaluation practices and complication rates Scand J Gastroenterol 32 1168 1173 9399400
294. RA Lencioni HP Allgaier D Cioni M Olschewski P Deibert L Crocetti, et al. 2003 Small hepatocellular carcinoma in cirrhosis: randomized comparison of radio-frequency thermal ablation versus percutaneous ethanol injection Radiology 228 235 240 12759473
295. SM Lin CJ Lin CC Lin CW Hsu YC Chen 2004 Radiofrequency ablation improves prognosis compared with ethanol injection for hepatocellular carcinoma ≥4 cm Gastroenterology 127 1714 1723 15578509
296. S Shiina T Teratani S Obi S Sato R Tateishi T Fujishima, et al. 2005 A randomized controlled trial of radiofrequency ablation with ethanol injection for small hepatocellular carcinoma Gastroenterology 129 122 130 16012942
297. SM Lin CJ Lin CC Lin CW Hsu YC Chen 2005 Randomised controlled trial comparing percutaneous radiofrequency thermal ablation, percutaneous ethanol injection, and percutaneous acetic acid injection to treat hepatocellular carcinoma of 3 cm or less Gut 54 1151 1156 1:CAS:528:DC%2BD2MXpt1ersrs%3D 16009687
298. T Shibata Y Iimuro Y Yamamoto Y Maetani F Ametani K Itoh, et al. 2002 Small hepatocellular carcinoma: comparison of radio-frequency ablation and percutaneous microwave coagulation therapy Radiology 223 331 337 11997534
299. J Machi RS Bueno LL Wong 2005 Long-term follow-up outcome of patients undergoing radiofrequency ablation for unresectable hepatocellular carcinoma World J Surg 29 1364 1373 16240062
300. R Lencioni D Cioni L Crocetti C Franchini CD Pina J Lera, et al. 2005 Early-stage hepatocellular carcinoma in patients with cirrhosis: long-term results of percutaneous image-guided radiofrequency ablation Radiology 234 961 967 15665226 (Pubitemid 40250844)
301. R Tateishi S Shiina T Teratani S Obi S Sato Y Koike, et al. 2005 Percutaneous radiofrequency ablation for hepatocellular carcinoma. An analysis of 1000 cases Cancer 103 1201 1209 15690326 (Pubitemid 40328091)
302. P Cabassa F Donato F Simeone L Grazioli L Romanini 2006 Radiofrequency ablation of hepatocellular carcinoma: long-term experience with expandable needle electrodes AJR Am J Roentgenol 186 S316 S321 16632694
303. T Livraghi F Meloni M Di Stasi E Rolle L Solbiati C Tinelli, et al. 2008 Sustained complete response and complications rates after radiofrequency ablation of very early hepatocellular carcinoma in cirrhosis: is resection still the treatment of choice? Hepatology 47 82 89 18008357
304. K Yan MH Chen W Yang YB Wang W Gao CY Hao, et al. 2008 Radiofrequency ablation of hepatocellular carcinoma: long-term outcome and prognostic factors Eur J Radiol 67 336 347 17765421 (Pubitemid 351952310)
305. H Kasugai Y Osaki H Oka M Kudo T Seki 2007 Severe complications of radiofrequency ablation therapy for hepatocellular carcinoma: an analysis of 3,891 ablations in 2,614 patients Oncology 72 Suppl 1 72 75 18087185
306. BQ Cheng CQ Jia CT Liu W Fan QL Wang ZL Zhang, et al. 2008 Chemoembolization combined with radiofrequency ablation for patients with hepatocellular carcinoma larger than 3 cm: a randomized controlled trial JAMA 299 1669 1677 1:CAS:528:DC%2BD1cXks1Wmtrw%3D 18398079
307. M Kobayashi K Ikeda Y Kawamura T Hosaka H Sezaki H Yatsuji, et al. 2007 Randomized controlled trial for the efficacy of hepatic arterial occlusion during radiofrequency ablation for small hepatocellular carcinoma-direct ablative effects and a long-term outcome Liver Int 27 353 359 17355457
308. GT Huang PH Lee YM Tsang MY Lai PM Yang RH Hu, et al. 2005 Percutaneous ethanol injection versus surgical resection for the treatment of small hepatocellular carcinoma: a prospective study Ann Surg 242 36 42 15973099
309. MS Chen JQ Li Y Zheng RP Guo HH Liang YQ Zhang, et al. 2006 A prospective randomized trial comparing percutaneous local ablative therapy and partial hepatectomy for small hepatocellular carcinoma Ann Surg 243 321 328 16495695
310. A Castells J Bruix C Bru J Fuster R Vilana M Navasa, et al. 1993 Treatment of small hepatocellular carcinoma in cirrhotic patients: a cohort study comparing surgical resection and percutaneous ethanol injection Hepatology 18 1121 1126 1:STN:280:DyaK2c%2FktFWqtA%3D%3D 8225217
311. T Livraghi L Bolondi L Buscarini M Cottone A Mazziotti A Morabito, et al. 1995 No treatment, resection and ethanol injection in hepatocellular carcinoma: a retrospective analysis of survival in 391 patients with cirrhosis. Italian Cooperative HCC Study Group J Hepatol 22 522 526 1:STN:280:DyaK2MznvVKitg%3D%3D 7650331
312. M Ryu Y Shimamura T Kinoshita M Konishi N Kawano M Iwasaki, et al. 1997 Therapeutic results of resection, transcatheter arterial embolization and percutaneous transhepatic ethanol injection in 3225 patients with hepatocellular carcinoma: a retrospective multicenter study Jpn J Clin Oncol 27 251 257 1:STN:280:DyaK1c%2FitFKmsA%3D%3D 9379514
313. T Nakashima M Kojiro 1986 Pathologic characteristics of hepatocellular carcinoma Semin Liver Dis 6 259 266 1:STN:280:DyaL2s%2Fkt1ymtw%3D%3D 3022387
314. YN Park CP Yang GJ Fernandez O Cubukcu SN Thung ND Theise 1998 Neoangiogenesis and sinusoidal "capillarization" in dysplastic nodules of the liver Am J Surg Pathol 22 656 662 1:STN:280:DyaK1c3pt1Whtg%3D%3D 9630172
315. N Goseki T Nosaka M Endo M Koike 1995 Nourishment of hepatocellular carcinoma cells through the portal blood flow with and without transcatheter arterial embolization Cancer 76 736 742 1:STN:280:DyaK283itlSqtQ%3D%3D 8625174
316. J Bruix M Sala JM Llovet 2004 Chemoembolization for hepatocellular carcinoma Gastroenterology 127 S179 S188 1:CAS:528:DC%2BD2cXhtVGmtb%2FF 15508083
317. R Yamada M Sato M Kawabata H Nakatsuka K Nakamura S Takashima 1983 Hepatic artery embolization in 120 patients with unresectable hepatoma Radiology 148 397 401 1:STN:280:DyaL3s3kvVWhsA%3D%3D 6306721
318. DE Ramsey LY Kernagis MC Soulen JF Geschwind 2002 Chemoembolization of hepatocellular carcinoma J Vasc Interv Radiol 13 S211 S221 12354839
319. JB Kruskal L Hlatky P Hahnfeldt K Teramoto KR Stokes ME Clouse 1993 In vivo and in vitro analysis of the effectiveness of doxorubicin combined with temporary arterial occlusion in liver tumors J Vasc Interv Radiol 4 741 747 1:STN:280:DyaK2c7gvVaisQ%3D%3D 8280994
320. E Liapi JF Geschwind 2007 Transcatheter and ablative therapeutic approaches for solid malignancies J Clin Oncol 25 978 986 17350947
321. L Marelli R Stigliano C Triantos M Senzolo E Cholongitas N Davies, et al. 2007 Transarterial therapy for hepatocellular carcinoma: which technique is more effective? A systematic review of cohort and randomized studies Cardiovasc Intervent Radiol 30 6 25 17103105
322. Vogl TJ, Naguib NN, Nour-Eldin NE, Rao P, Emami AH, Zangos S, et al. Review on transarterial chemoembolization in hepatocellular carcinoma: palliative, combined, neoadjuvant, bridging, and symptomatic indications. Eur J Radiol 2009;72:505-516
323. M Makuuchi M Sukigara T Mori J Kobayashi S Yamazaki H Hasegawa, et al. 1985 Bile duct necrosis: complication of transcatheter hepatic arterial embolization Radiology 156 331 334 1:STN:280:DyaL2M3ktlerug%3D%3D 2989972
324. M Varela MI Real M Burrel A Forner M Sala M Brunet, et al. 2007 Chemoembolization of hepatocellular carcinoma with drug eluting beads: efficacy and doxorubicin pharmacokinetics J Hepatol 46 474 481 1:CAS:528: DC%2BD2sXhtlCmtb0%3D 17239480
325. S Iwamoto H Sanefuji K Okuda 2003 Angiographic subsegmentectomy for the treatment of patients with small hepatocellular carcinoma Cancer 97 1051 1056 12569605
326. O Matsui M Kadoya J Yoshikawa T Gabata K Arai H Demachi, et al. 1993 Small hepatocellular carcinoma: treatment with subsegmental transcatheter arterial embolization Radiology 188 79 83 1:STN:280:DyaK3s3ovV2jtA%3D%3D 8390073
327. S Miyayama O Matsui M Yamashiro Y Ryu K Kaito K Ozaki, et al. 2007 Ultraselective transcatheter arterial chemoembolization with a 2-F tip microcatheter for small hepatocellular carcinomas: relationship between local tumor recurrence and visualization of the portal vein with iodized oil J Vasc Interv Radiol 18 365 376 17377182
328. M Nakai M Sato N Kawai H Minamiguchi M Masuda H Tanihata, et al. 2001 Hepatocellular carcinoma: involvement of the internal mammary artery Radiology 219 147 152 1:STN:280:DC%2BD3M7oslKhtQ%3D%3D 11274549
329. JW Chung HC Kim JH Yoon HS Lee HJ Jae W Lee, et al. 2006 Transcatheter arterial chemoembolization of hepatocellular carcinoma: prevalence and causative factors of extrahepatic collateral arteries in 479 patients Korean J Radiol 7 257 266 17143029
330. S Miyayama O Matsui K Taki T Minami Y Ryu C Ito, et al. 2006 Extrahepatic blood supply to hepatocellular carcinoma: angiographic demonstration and transcatheter arterial chemoembolization Cardiovasc Intervent Radiol 29 39 48 16328697
331. CM Lo H Ngan WK Tso CL Liu CM Lam RT Poon, et al. 2002 Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma Hepatology 35 1164 1171 1:CAS:528:DC%2BD38XktF2hu7w%3D 11981766
332. JM Llovet MI Real X Montana R Planas S Coll J Aponte, et al. 2002 Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial Lancet 359 1734 1739 12049862
333. JM Llovet J Bruix 2003 Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival Hepatology 37 429 442 1:CAS:528:DC%2BD3sXhsFeltrg%3D 12540794
334. J Bruix M Sherman JM Llovet M Beaugrand R Lencioni AK Burroughs 2001 et al. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL Conference. European Association for the Study of the Liver J Hepatol 35 421 430 1:STN:280:DC%2BD3MrksFCmtg%3D%3D 11592607
335. J Bruix M Sherman 2005 Management of hepatocellular carcinoma Hepatology 42 1208 1236 16250051
336. FY Yao R Hirose JM LaBerge TJ Davern III NM Bass RK Kerlan Jr, et al. 2005 A prospective study on downstaging of hepatocellular carcinoma prior to liver transplantation Liver Transpl 11 1505 1514 16315294
337. AJ Hanje FY Yao 2008 Current approach to down-staging of hepatocellular carcinoma prior to liver transplantation Curr Opin Organ Transplant 13 234 240 18685309
338. FY Yao RK Kerlan Jr R Hirose TJ Davern III NM Bass S Feng, et al. 2008 Excellent outcome following down-staging of hepatocellular carcinoma prior to liver transplantation: an intention-to-treat analysis Hepatology 48 819 827 18688876
339. M Staunton JD Dodd PA McCormick DE Malone 2005 Finding evidence-based answers to practical questions in radiology: which patients with inoperable hepatocellular carcinoma will survive longer after transarterial chemoembolization? Radiology 237 404 413 16244249
340. AO Chan MF Yuen CK Hui WK Tso CL Lai 2002 A prospective study regarding the complications of transcatheter intraarterial lipiodol chemoembolization in patients with hepatocellular carcinoma Cancer 94 1747 1752 11920537
341. JW Chung JH Park JK Han BI Choi MC Han HS Lee, et al. 1996 Hepatic tumors: predisposing factors for complications of transcatheter oily chemoembolization Radiology 198 33 40 1:STN:280:DyaK287itlWguw%3D%3D 8539401
342. E Caturelli DA Siena S Fusilli MR Villani G Schiavone M Nardella, et al. 2000 Transcatheter arterial chemoembolization for hepatocellular carcinoma in patients with cirrhosis: evaluation of damage to nontumorous liver tissue-long-term prospective study Radiology 215 123 128 1:STN:280: DC%2BD3c3hslWrsw%3D%3D 10751477
343. JM Llovet J Bruix 2008 Novel advancements in the management of hepatocellular carcinoma in 2008 J Hepatol 48 Suppl 1 S20 S37 1:CAS:528:DC%2BD1cXjtlelsL0%3D 18304676
344. JM Llovet J Bruix 2008 Molecular targeted therapies in hepatocellular carcinoma Hepatology 48 1312 1327 1:CAS:528:DC%2BD1cXht1Khu7zP 18821591
345. JM Llovet S Ricci V Mazzaferro P Hilgard E Gane JF Blanc, et al. 2008 Sorafenib in advanced hepatocellular carcinoma N Engl J Med 359 378 390 1:CAS:528:DC%2BD1cXovFWjsL8%3D 18650514
346. AL Cheng YK Kang Z Chen CJ Tsao S Qin JS Kim, et al. 2009 Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial Lancet Oncol 10 25 34 1:CAS:528:DC%2BD1cXhsFChtbnM 19095497
347. S Wilhelm C Carter M Lynch T Lowinger J Dumas RA Smith, et al. 2006 Discovery and development of sorafenib: a multikinase inhibitor for treating cancer Nat Rev Drug Discov 5 835 844 1:CAS:528:DC%2BD28XhtVajsbbM 17016424
348. Miller AA, Murry DJ, Owzar K, Hollis DR, Abou-Alfa GK, Desai A, et al. Pharmacokinetic (PK) and phase I study of sorafenib (S) for solid tumors and hematologic malignancies in patients with hepatic or renal dysfunction (HD or RD): CALGB 60301. J Clin Oncol 2007;25:3538 (abstract)
349. Abou-Alfa GK, Amadori D, Santoro A, Figer JDG A, Lathia C, Voliotis D, et al. Is sorafenib (S) safe and effective in patients (pts) with hepatocellular carcinoma (HCC) and Child-Pugh B (CPB) cirrhosis? J Clin Oncol 2008;26:4518 (abstract)
350. AB Siegel EI Cohen A Ocean D Lehrer A Goldenberg JJ Knox, et al. 2008 Phase II trial evaluating the clinical and biologic effects of bevacizumab in unresectable hepatocellular carcinoma J Clin Oncol 26 2992 2998 1:CAS:528:DC%2BD1cXoslOqsL0%3D 18565886
351. LQ Chow SG Eckhardt 2007 Sunitinib: from rational design to clinical efficacy J Clin Oncol 25 884 896 1:CAS:528:DC%2BD2sXjvVKmtLY%3D 17327610
352. Zhu AX, Sahani DV, di Tomaso E, Duda DG, Catalano OA, Ancukiewicz M, et al. Sunitinib monotherapy in patients with advanced hepatocellular carcinoma (HCC): insights from a multidisciplinary phase II study. J Clin Oncol 2008;26:4521 (abstract)
353. Faivre SJ, Raymond E, Douillard J, Boucher E, Lim HY, Kim JS, et al. Assessment of safety and drug-induced tumor necrosis with sunitinib in patients (pts) with unresectable hepatocellular carcinoma (HCC). J Clin Oncol 2007;25:3546 (abstract)
354. RJ D'Amato MS Loughnan E Flynn J Folkman 1994 Thalidomide is an inhibitor of angiogenesis Proc Natl Acad Sci U S A 91 4082 4085 7513432
355. FE Kruse AM Joussen K Rohrschneider MD Becker HE Volcker 1998 Thalidomide inhibits corneal angiogenesis induced by vascular endothelial growth factor Graefes Arch Clin Exp Ophthalmol 236 461 466 1:CAS:528:DyaK1cXkt1Kmsrs%3D 9646092
356. C Hsu CN Chen LT Chen CY Wu PM Yang MY Lai, et al. 2003 Low-dose thalidomide treatment for advanced hepatocellular carcinoma Oncology 65 242 249 1:CAS:528:DC%2BD3sXpsVOjs7s%3D 14657598
357. YZ Patt MM Hassan RD Lozano AK Nooka II Schnirer JB Zeldis, et al. 2005 Thalidomide in the treatment of patients with hepatocellular carcinoma: a phase II trial Cancer 103 749 755 1:CAS:528:DC%2BD2MXit1Ggsrs%3D 15660400
358. AY Lin N Brophy GA Fisher S So C Biggs TI Yock, et al. 2005 Phase II study of thalidomide in patients with unresectable hepatocellular carcinoma Cancer 103 119 125 1:CAS:528:DC%2BD2MXmtVarsQ%3D%3D 15565573
359. C Hsu CN Chen LT Chen CY Wu FJ Hsieh AL Cheng 2005 Effect of thalidomide in hepatocellular carcinoma: assessment with power Doppler US and analysis of circulating angiogenic factors Radiology 235 509 516 15858091
360. J Wang LT Chen YM Tsang TW Liu TT Shih 2004 Dynamic contrast-enhanced MRI analysis of perfusion changes in advanced hepatocellular carcinoma treated with an antiangiogenic agent: a preliminary study AJR Am J Roentgenol 183 713 719 15333360
361. K Breuhahn T Longerich P Schirmacher 2006 Dysregulation of growth factor signaling in human hepatocellular carcinoma Oncogene 25 3787 3800 1:CAS:528:DC%2BD28XmtFCntL0%3D 16799620
362. M Ono K Morisawa J Nie K Ota T Taniguchi T Saibara, et al. 1998 Transactivation of transforming growth factor alpha gene by hepatitis B virus preS1 Cancer Res 58 1813 1816 1:CAS:528:DyaK1cXislensbg%3D 9581818
363. Y Sato J Kato R Takimoto K Takada Y Kawano K Miyanishi, et al. 2006 Hepatitis C virus core protein promotes proliferation of human hepatoma cells through enhancement of transforming growth factor alpha expression via activation of nuclear factor-kappaB Gut 55 1801 1808 1:CAS:528: DC%2BD2sXkvFOjug%3D%3D 16581947
364. JL Jakubczak FV Chisari G Merlino 1997 Synergy between transforming growth factor alpha and hepatitis B virus surface antigen in hepatocellular proliferation and carcinogenesis Cancer Res 57 3606 3611 1:CAS:528: DyaK2sXls1Sgs7w%3D 9270035
365. A Kiss NJ Wang JP Xie SS Thorgeirsson 1997 Analysis of transforming growth factor (TGF)-alpha/epidermal growth factor receptor, hepatocyte growth factor/c-met, TGF-beta receptor type II, and p53 expression in human hepatocellular carcinomas Clin Cancer Res 3 1059 1066 1:CAS:528: DyaK2sXkvFCgs7k%3D 9815784
366. CH Yang 2008 EGFR tyrosine kinase inhibitors for the treatment of NSCLC in East Asia: present and future Lung Cancer 60 Suppl 2 S23 S30 18513581
367. MC Su HC Lien YM Jeng 2005 Absence of epidermal growth factor receptor exon 18-21 mutation in hepatocellular carcinoma Cancer Lett 224 117 121 1:CAS:528:DC%2BD2MXks1aktr8%3D 15911107
368. PA Philip MR Mahoney C Allmer J Thomas HC Pitot G Kim, et al. 2005 Phase II study of erlotinib (OSI-774) in patients with advanced hepatocellular cancer J Clin Oncol 23 6657 6663 1:CAS:528:DC%2BD2MXhtFWqsLbJ 16170173 (Pubitemid 46190260)
369. MB Thomas R Chadha K Glover X Wang J Morris T Brown, et al. 2007 Phase 2 study of erlotinib in patients with unresectable hepatocellular carcinoma Cancer 110 1059 1067 1:CAS:528:DC%2BD2sXhtVChs7fJ 17623837
370. O'Dwyer PJ, Giantonio BJ, Levy DE, Kauh JS, Fitzgerald DB, Benson AB. Gefitinib in advanced unresectable hepatocellular carcinoma: results from the Eastern Cooperative Oncology Group's Study E1203. J Clin Oncol 2006;24:4143 (abstract)
371. AX Zhu K Stuart LS Blaszkowsky A Muzikansky DP Reitberg JW Clark, et al. 2007 Phase 2 study of cetuximab in patients with advanced hepatocellular carcinoma Cancer 110 581 589 1:CAS:528:DC%2BD2sXpt1yqu7s%3D 17583545
372. C Hsu JC Cheng AL Cheng 2004 Recent advances in non-surgical treatment for advanced hepatocellular carcinoma J Formos Med Assoc 103 483 495 15318270
373. AX Zhu 2006 Systemic therapy of advanced hepatocellular carcinoma: how hopeful should we be? Oncologist 11 790 800 1:CAS:528:DC%2BD28XhtFKlsb7J 16880238
374. PM Lopez A Villanueva JM Llovet 2006 Systematic review: evidence-based management of hepatocellular carcinoma-an updated analysis of randomized controlled trials Aliment Pharmacol Ther 23 1535 1547 1:STN:280: DC%2BD283mslensw%3D%3D 16696801
375. W Yeo TS Mok B Zee TW Leung PB Lai WY Lau, et al. 2005 A randomized phase III study of doxorubicin versus cisplatin/interferon alpha-2b/doxorubicin/ fluorouracil (PIAF) combination chemotherapy for unresectable hepatocellular carcinoma J Natl Cancer Inst 97 1532 1538 1:CAS:528:DC%2BD2MXhtFCjtb7O 16234567
376. RG Gish C Porta L Lazar P Ruff R Feld A Croitoru, et al. 2007 Phase III randomized controlled trial comparing the survival of patients with unresectable hepatocellular carcinoma treated with nolatrexed or doxorubicin J Clin Oncol 25 3069 3075 1:CAS:528:DC%2BD2sXptlGrsbc%3D 17634485
377. CL Lai PC Wu GC Chan AS Lok HJ Lin 1988 Doxorubicin versus no antitumor therapy in inoperable hepatocellular carcinoma. A prospective randomized trial Cancer 62 479 483 1:STN:280:DyaL1c3ntVeisg%3D%3D 2839280
378. TS Yang YC Lin JS Chen HM Wang CH Wang 2000 Phase II study of gemcitabine in patients with advanced hepatocellular carcinoma Cancer 89 750 756 1:CAS:528:DC%2BD3cXmtFOnu74%3D 10951336
379. Z Guan Y Wang S Maoleekoonpairoj Z Chen WS Kim V Ratanatharathorn, et al. 2003 Prospective randomised phase II study of gemcitabine at standard or fixed dose rate schedule in unresectable hepatocellular carcinoma Br J Cancer 89 1865 1869 1:CAS:528:DC%2BD3sXovVers7s%3D 14612894
380. Y Yen DW Lim V Chung RJ Morgan LA Leong SI Shibata, et al. 2008 Phase II study of oxaliplatin in patients with unresectable, metastatic, or recurrent hepatocellular cancer: a California Cancer Consortium Trial Am J Clin Oncol 31 317 322 1:CAS:528:DC%2BD1cXpvFKnsbg%3D 18845988
381. YZ Patt MM Hassan A Aguayo AK Nooka RD Lozano SA Curley, et al. 2004 Oral capecitabine for the treatment of hepatocellular carcinoma, cholangiocarcinoma, and gallbladder carcinoma Cancer 101 578 586 1:CAS:528:DC%2BD2cXmslChs74%3D 15274071
382. S Louafi V Boige M Ducreux L Bonyhay T Mansourbakht T de Baere, et al. 2007 Gemcitabine plus oxaliplatin (GEMOX) in patients with advanced hepatocellular carcinoma (HCC): results of a phase II study Cancer 109 1384 1390 1:CAS:528:DC%2BD2sXkslKitbw%3D 17330837
383. V Boige JL Raoul JP Pignon O Bouche JF Blanc L Dahan, et al. 2007 Multicentre phase II trial of capecitabine plus oxaliplatin (XELOX) in patients with advanced hepatocellular carcinoma: FFCD 03-03 trial Br J Cancer 97 862 867 1:CAS:528:DC%2BD2sXhtFSnurfN 17876335 (Pubitemid 47519302)
384. Abou-Alfa GK, Johnson P, Knox J, Lacava J, Leung T, Mori A, et al. Preliminary results from a phase II, randomized, double-blind study of sorafenib plus doxorubicin versus placebo plus doxorubicin in patients with advanced hepatocellular carcinoma. In Proceedings of the 14th European cancer conference of the European Cancer Organisation (ECCO). Barcelona: ECCO; 2007. pp 23-27 (abstract no.: 3500)
385. AX Zhu LS Blaszkowsky DP Ryan JW Clark A Muzikansky K Horgan, et al. 2006 Phase II study of gemcitabine and oxaliplatin in combination with bevacizumab in patients with advanced hepatocellular carcinoma J Clin Oncol 24 1898 1903 1:CAS:528:DC%2BD28XkvVajtb8%3D 16622265
386. Sun W, Haller DG, Mykulowycz K, Rosen M, Soulen M, Capparo M, et al. Combination of capecitabine, oxaliplatin with bevacizumab in treatment of advanced hepatocellular carcinoma (HCC): a phase II study. J Clin Oncol 2007;25:4547 (abstract)
387. A Asnacios L Fartoux O Romano C Tesmoingt SS Louafi T Mansoubakht, et al. 2008 Gemcitabine plus oxaliplatin (GEMOX) combined with cetuximab in patients with progressive advanced stage hepatocellular carcinoma: results of a multicenter phase 2 study Cancer 112 2733 2739 1:CAS:528:DC%2BD1cXosVGgsr4%3D 18412149
388. O'Neil BH, Bernard SA, Goldberg RM, Moore DT, Garcia R, Marroquin C, et al. Phase II study of oxaliplatin, capecitabine, and cetuximab in advanced hepatocellular carcinoma. J Clin Oncol 2008;26(Suppl):4604 (abstract)
389. Hsu CH, Yang T, Hsu C, Toh H, Epstein R, Hsiao L, et al. Phase II study of bevacizumab (A) plus capecitabine (X) in patients (pts) with advanced/metastatic hepatocellular carcinoma (HCC): final report. J Clin Oncol 2008;26(Suppl):4603 (abstr)
390. Thomas MB, Chadha R, Iwasaki M, Glover K, Abbruzzese JL. The combination of bevacizumab (B) and erlotinib (E) shows significant biological activity in patients with advanced hepatocellular carcinoma (HCC). J Clin Oncol 2007;25(Suppl):4567 (abstract)
391. CM Lo CL Liu SC Chan CM Lam RT Poon IO Ng, et al. 2007 A randomized, controlled trial of postoperative adjuvant interferon therapy after resection of hepatocellular carcinoma Ann Surg 245 831 842 17522506
392. SM Lin CJ Lin CW Hsu DI Tai IS Sheen DY Lin, et al. 2004 Prospective randomized controlled study of interferon-alpha in preventing hepatocellular carcinoma recurrence after medical ablation therapy for primary tumors Cancer 100 376 382 1:CAS:528:DC%2BD2cXhtVOgsrs%3D 14716774
393. T Kuzuya Y Katano T Kumada H Toyoda I Nakano Y Hirooka, et al. 2007 Efficacy of antiviral therapy with lamivudine after initial treatment for hepatitis B virus-related hepatocellular carcinoma J Gastroenterol Hepatol 22 1929 1935 1:CAS:528:DC%2BD2sXhtlOltb3O 17914972
394. CY Piao S Fujioka Y Iwasaki K Fujio T Kaneyoshi Y Araki, et al. 2005 Lamivudine treatment in patients with HBV-related hepatocellular carcinoma-using an untreated, matched control cohort Acta Med Okayama 59 217 224 1:CAS:528:DC%2BD2MXht1WjtrnI 16286955
395. JW Jang JY Choi SH Bae SK Yoon UI Chang CW Kim, et al. 2006 A randomized controlled study of preemptive lamivudine in patients receiving transarterial chemo-lipiodolization Hepatology 43 233 240 1:CAS:528:DC%2BD28XhvVSnsr4%3D 16440357
396. T Kumada S Nakano I Takeda K Sugiyama T Osada S Kiriyama, et al. 1997 Patterns of recurrence after initial treatment in patients with small hepatocellular carcinoma Hepatology 25 87 92 1:STN:280:DyaK2s7jvVantg%3D%3D 8985270
397. RT Poon ST Fan IO Ng CM Lo CL Liu J Wong 2000 Different risk factors and prognosis for early and late intrahepatic recurrence after resection of hepatocellular carcinoma Cancer 89 500 507 1:STN:280:DC%2BD3cvgt1aktg%3D%3D 10931448
398. M Sakon K Umeshita H Nagano H Eguchi S Kishimoto A Miyamoto, et al. 2000 Clinical significance of hepatic resection in hepatocellular carcinoma: analysis by disease-free survival curves Arch Surg 135 1456 1459 1:STN:280: DC%2BD3M7htVemsw%3D%3D 11115352
399. K Ikeda Y Arase S Saitoh M Kobayashi Y Suzuki F Suzuki, et al. 2000 Interferon beta prevents recurrence of hepatocellular carcinoma after complete resection or ablation of the primary tumor-a prospective randomized study of hepatitis C virus-related liver cancer Hepatology 32 228 232 1:CAS:528:DC%2BD3cXlvVyjtrk%3D 10915728
400. S Kubo S Nishiguchi K Hirohashi H Tanaka T Shuto O Yamazaki, et al. 2001 Effects of long-term postoperative interferon-alpha therapy on intrahepatic recurrence after resection of hepatitis C virus-related hepatocellular carcinoma. A randomized, controlled trial Ann Intern Med 134 963 967 1:CAS:528:DC%2BD3MXktF2gs70%3D 11352697
401. Y Shiratori S Shiina T Teratani M Imamura S Obi S Sato, et al. 2003 Interferon therapy after tumor ablation improves prognosis in patients with hepatocellular carcinoma associated with hepatitis C virus Ann Intern Med 138 299 306 12585827
402. CH Hung CM Lee JH Wang HD Tung CH Chen SN Lu 2005 Antiviral therapy after non-surgical tumor ablation in patients with hepatocellular carcinoma associated with hepatitis C virus J Gastroenterol Hepatol 20 1553 1559 1:CAS:528:DC%2BD2MXhtFygsrrO 16174073
403. V Mazzaferro R Romito M Schiavo L Mariani T Camerini S Bhoori, et al. 2006 Prevention of hepatocellular carcinoma recurrence with alpha-interferon after liver resection in HCV cirrhosis Hepatology 44 1543 1554 1:CAS:528:DC%2BD2sXislKktQ%3D%3D 17133492
404. Y Sakaguchi M Kudo T Fukunaga Y Minami H Chung T Kawasaki 2005 Low-dose, long-term, intermittent interferon-alpha-2b therapy after radical treatment by radiofrequency ablation delays clinical recurrence in patients with hepatitis C virus-related hepatocellular carcinoma Intervirology 48 64 70 1:CAS:528:DC%2BD2MXisFyhtL8%3D 15785092
405. S Nishiguchi A Tamori S Kubo 2005 Effect of long-term postoperative interferon therapy on intrahepatic recurrence and survival rate after resection of hepatitis C virus-related hepatocellular carcinoma Intervirology 48 71 75 1:CAS:528:DC%2BD2MXisFyhtLw%3D 15785093
406. K Hasegawa T Takayama M Ijichi Y Matsuyama H Imamura K Sano, et al. 2006 Uracil-tegafur as an adjuvant for hepatocellular carcinoma: a randomized trial Hepatology 44 891 895 1:CAS:528:DC%2BD28XhtFyqsrzP 17006925
407. Y Muto H Moriwaki M Ninomiya S Adachi A Saito KT Takasaki, et al. 1996 Prevention of second primary tumors by an acyclic retinoid, polyprenoic acid, in patients with hepatocellular carcinoma. Hepatoma Prevention Study Group N Engl J Med 334 1561 1567 1:CAS:528:DyaK28XksVCgsLk%3D 8628336 (Pubitemid 26177483)
408. K Takai M Okuno I Yasuda R Matsushima-Nishiwaki T Uematsu H Tsurumi, et al. 2005 Prevention of second primary tumors by an acyclic retinoid in patients with hepatocellular carcinoma. Updated analysis of the long-term follow-up data Intervirology 48 39 45 1:CAS:528:DC%2BD2MXisFyht7Y%3D 15785088
409. C Hirayama M Okumura K Tanikawa M Yano M Mizuta N Ogawa 1989 A multicenter randomized controlled clinical trial of Shosaiko-to in chronic active hepatitis Gastroenterol Jpn 24 715 719 1:STN:280:DyaK3c7gvVGhuw%3D%3D 2691317
410. H Oka S Yamamoto T Kuroki S Harihara T Marumo SR Kim, et al. 1995 Prospective study of chemoprevention of hepatocellular carcinoma with Sho-saiko-to (TJ-9) Cancer 76 743 749 1:CAS:528:DyaK2MXosVejsL0%3D 8625175
411. I Shimizu YR Ma Y Mizobuchi F Liu T Miura Y Nakai, et al. 1999 Effects of Sho-saiko-to, a Japanese herbal medicine, on hepatic fibrosis in rats Hepatology 29 149 160 1:CAS:528:DyaK1MXjslWnug%3D%3D 9862861
412. G Shiota Y Maeta T Mukoyama A Yanagidani A Udagawa K Oyama, et al. 2002 Effects of Sho-Saiko-to on hepatocarcinogenesis and 8-hydroxy-2′- deoxyguanosine formation Hepatology 35 1125 1133 11981762
413. M Tsuchiya H Kono M Matsuda H Fujii I Rusyn 2008 Protective effect of Juzen-taiho-to on hepatocarcinogenesis is mediated through the inhibition of Kupffer cell-induced oxidative stress Int J Cancer 123 2503 2511 1:CAS:528:DC%2BD1cXhtlyru7vO 18785209